# The PCOS Phenotypes in Unselected Populations (P-PUP) study: participant clinical features and data harmonization on analysis of individual participant data.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12261540</article-id><article-id pub-id-type="pmid">40660246</article-id>
<article-id pub-id-type="publisher-id">4221</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04221-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The PCOS Phenotypes in Unselected Populations (P-PUP) study: participant clinical features and data harmonization on analysis of individual participant data</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bizuneh</surname><given-names>Asmamaw Demis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiconco</surname><given-names>Sylvia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Earnest</surname><given-names>Arul</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Khomami</surname><given-names>Mahnaz Bahri</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dhungana</surname><given-names>Raja Ram</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Azziz</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Suturina</surname><given-names>Larisa V.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Xiaomiao</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Gambineri</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tehrani</surname><given-names>Fahimeh Ramezani</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Yildiz</surname><given-names>Bulent O.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jin Ju</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Liangzhi</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Makwe</surname><given-names>Christian Chigozie</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Teede</surname><given-names>Helena J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Joham</surname><given-names>Anju E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Tay</surname><given-names>Chau Thien</given-names></name><address><email>jillian.tay@monash.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bfwt286</institution-id><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution>Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, </institution><institution>Monash University, </institution></institution-wrap>Melbourne, VIC 3168 Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02bfwt286</institution-id><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution>School of Public Health and Preventive Medicine, </institution><institution>Monash University, </institution></institution-wrap>Melbourne, VIC 3004 Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/008s83205</institution-id><institution-id institution-id-type="GRID">grid.265892.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0634 4187</institution-id><institution>Departments of Obstetrics and Gynecology, and Medicine, </institution><institution>University of Alabama at Birmingham, </institution></institution-wrap>Birmingham, AL 35294 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/027n02r78</institution-id><institution-id institution-id-type="GRID">grid.467106.2</institution-id><institution>Department of Reproductive Health Protection, </institution><institution>Scientific Center for Family Health and Human Reproduction Problems, </institution></institution-wrap>Irkutsk, 664003 Russian Federation </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01vjw4z39</institution-id><institution-id institution-id-type="GRID">grid.284723.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 8877 7471</institution-id><institution>Department of Reproductive Medicine, Guangdong Provincial People&#x02019;s Hospital (Guangdong Academy of Medical Sciences), </institution><institution>Southern Medical University, </institution></institution-wrap>106 Zhongshan 2 Road, Guangzhou, 510080 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01111rn36</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution>Department of Medical and Surgical Science-DIMEC, Division of Endocrinology and Diabetes Prevention and Care, </institution><institution>IRCCS Azienda Ospedaliero-Universitaria Di Bologna, </institution></institution-wrap>Via Massarenti 9, Bologna, 40138 Italy </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>24 Parvaneh, Yaman Street, Velenjak, Tehran, 19395-4763 Iran </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04kwvgz42</institution-id><institution-id institution-id-type="GRID">grid.14442.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2342 7339</institution-id><institution>Division of Endocrinology and Metabolism, Department of Internal Medicine, </institution><institution>Hacettepe University School of Medicine, </institution></institution-wrap>Ankara, 06100 Turkey </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01z4nnt86</institution-id><institution-id institution-id-type="GRID">grid.412484.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0302 820X</institution-id><institution>Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Healthcare System Gangnam Center, </institution><institution>Seoul National University Hospital, </institution></institution-wrap>Seoul, 06236 Republic of Korea </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00726et14</institution-id><institution-id institution-id-type="GRID">grid.461863.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9397</institution-id><institution>Department of Obstetrics and Gynecology, </institution><institution>West China Second University Hospital, Sichuan University, </institution></institution-wrap>Chengdu, 610041 China </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05rk03822</institution-id><institution-id institution-id-type="GRID">grid.411782.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1803 1817</institution-id><institution>Department of Obstetrics and Gynaecology, College of Medicine, </institution><institution>University of Lagos, Idi-Araba, Lagos, Nigeria, </institution></institution-wrap>P.M.B. 12003, Surulere, Lagos, Nigeria </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02t1bej08</institution-id><institution-id institution-id-type="GRID">grid.419789.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9295 3933</institution-id><institution>Department of Endocrinology and Diabetes, </institution><institution>Monash Health, </institution></institution-wrap>Clayton, Melbourne, VIC 3168 Australia </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>420</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par16">Polycystic ovary syndrome (PCOS) is a multifaceted condition with diagnostic challenges and clinical heterogeneity across populations. Research priorities include enhanced accuracy in defining cut-offs for diagnostic features. Here, we aim to describe participant clinical features and data harmonization in the international PCOS Phenotype in Unselected Populations (P-PUP) study.</p></sec><sec><title>Methods</title><p id="Par17">We searched EMBASE and Medline (Ovid) from 1990 to October 2, 2020, in population-based, medically unbiased study cohorts. Included studies had&#x02009;&#x02265;&#x02009;300 participants, directly assessed PCOS-related features, and provided Individual Participant Data (IPD). Risk of bias was assessed using the AXIS tool. Data integrity was ensured via cross-referencing, identifying outliers/implausible data, and variable harmonization. Reporting follows PRISMA-IPD guidelines, summarizing findings with frequencies and proportions.</p></sec><sec><title>Results</title><p id="Par18">The study included 9979 reproductive-age women from 12 studies across eight countries (China, Iran, Italy, Nigeria, Russia, South Korea, Turkey, and the USA), representing 11 ethnicities. Ovulatory dysfunction was variably recorded, from mean menstrual cycle length, minimum or maximum cycle length, number of cycles per year, or urinary progesterone measurements. Clinical hyperandrogenism was assessed via modified Ferriman&#x02013;Gallwey (mFG) scores, with a few also including acne and alopecia. Biochemical hyperandrogenism thresholds varied (95th, 97.5th, or 98th percentile of healthy controls). Polycystic ovary morphology was assessed via transvaginal, transabdominal, or transrectal approaches. Harmonization adhered to International PCOS Guidelines for ovulatory dysfunction, ethnicity-specific cut-offs for hirsutism (via <italic>k</italic>-means clustering), and 95th percentile thresholds for biochemical hyperandrogenism. PCOS prevalence ranged from 3.3 to 19.8% in the original studies and was 11.0% overall after harmonization.</p></sec><sec><title>Conclusions</title><p id="Par19">The P-PUP study offers an unprecedented, ethnically diverse, medically unbiased population-based cohort, an extraordinarily valuable tool to enhance knowledge and research in PCOS. However, variability in data collection methods and definitions of PCOS diagnostic features across studies limited the ability to fully integrate data for analysis. Despite these limitations, we optimized harmonization in this IPD, and the findings provided valuable insights into the challenges of data harmonization and established a foundation for future collaborative research. Future research should focus on standardizing data collection, establishing normative cut-offs based on true natural groupings, and linking diagnostic clusters to outcomes in diverse populations.</p></sec><sec><title>Protocol registration</title><p id="Par20">CRD42021267847.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04221-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Data harmonization</kwd><kwd>Androgens</kwd><kwd>Polycystic ovary syndrome</kwd><kwd>PCOS</kwd><kwd>Hirsutism</kwd><kwd>Acne</kwd><kwd>Female pattern hair loss</kwd><kwd>Polycystic ovary</kwd><kwd>Phenotype</kwd><kwd>Individual participant data</kwd><kwd>IPD</kwd></kwd-group><funding-group><award-group><funding-source><institution>Monash Graduate Scholarship (MGS) and the Monash International Tuition Scholarship (MITS)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>NHMRC fellowships</institution></funding-source><award-id>#2009326</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>NHMRC CRE-WhiRL fellowship</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>CRE-WHiRL funded by the NHMRC</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par42">Polycystic ovary syndrome (PCOS) is a complex endocrinopathy with significant long-term reproductive, metabolic, dermatological, and psychological health impacts [<xref ref-type="bibr" rid="CR1">1</xref>]. According to the 2023 International PCOS Guidelines criteria, diagnosis in adults is based on the presence of at least two of the following three criteria: (1) oligo-/anovulation (OA); (2) clinical or biochemical hyperandrogenism (HA); and (3) either polycystic ovary morphology (PCOM) on ultrasound or elevated serum anti-M&#x000fc;llerian hormone (AMH) levels [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. In adolescents, the diagnosis requires both OA and HA [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. It is estimated that 10&#x02013;13% of women worldwide are affected by PCOS, and the global incidence is reportedly increasing, making PCOS a major public health concern [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. PCOS and its associated health implications generate substantive health [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] and economic burdens for individuals, societies, and governments [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].
</p><p id="Par43">Despite increasing research and publications on PCOS [<xref ref-type="bibr" rid="CR13">13</xref>], the pathogenesis remains unclear and there are significant persisting challenges in diagnosis. This is attributable to its multifaceted and heterogeneous clinical presentation, the lack of gold-standard diagnostic tests, ethnic variation, and the fact that most studies are carried out in medically biased (clinically based) populations [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. It is also due to the multiple components of the diagnostic criteria, which are all continuous variables [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>], the paucity of data on normative cut-off thresholds for each diagnostic component within unselected, diverse populations [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], and the use of arbitrary diagnostic cut-offs across studies [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. This contributes to delayed or inaccurate diagnosis of PCOS, hindering timely and appropriate interventions to limit complications and treat the condition [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par44">These challenges underscore the importance of consolidating data from diverse populations for a more comprehensive understanding of the condition [<xref ref-type="bibr" rid="CR16">16</xref>]. While traditional systematic reviews and meta-analyses represent an improvement over single-center studies, they are limited by aggregated data from original studies with varying methodologies, sample sizes, and study populations. Conversely, the PCOS Phenotype in Unselected Populations (P-PUP) study, is a large-scale, international individual participant data (IPD) meta-analysis designed to address identified challenges, allowing harmonization of raw data from individual studies, standardization of cut-offs and analyses across studies and examination of individual-level variables to advance knowledge on PCOS etiology, diagnosis and clinical features in unselected community-based populations [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par45">This report on the P-PUP study aims to (a) outline the selection criteria and study identification process for the study, (b) describe the clinical features of the populations included, and (c) detail the data harmonization process for PCOS diagnostic criteria and features within the study.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Protocol and registration</title><p id="Par46">The protocol for the P-PUP study was registered in PROSPERO (ID: CRD42021267847) and published previously [<xref ref-type="bibr" rid="CR36">36</xref>]. This study was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Individual Participant Data guideline [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec4"><title>Selection of studies</title><p id="Par47">The methodology for the selection and identification of research groups and collaborators has been described previously [<xref ref-type="bibr" rid="CR36">36</xref>]. In summary, a systematic search of the EMBASE and Medline (Ovid) databases, along with a manual Google search, was conducted from 1990 to October 2, 2020, to identify eligible unselected population-based cohort studies. Key search terms included PCOS, ovulatory dysfunction (OD), hirsutism, polycystic ovary morphology (PCOM), and unselected populations, among others. A full search strategy for Medline (Ovid) is in Additional file 1: Table S1. The PCOS research community (RA and HJT) was consulted to identify any potentially ongoing or unpublished studies.</p><p id="Par48">Cross-sectional or longitudinal cohort studies were considered eligible if they were published after 1990 (after a change in diagnostic criteria), included a sample size of 300 or more unselected women of any age, ethnicity, or weight, and directly assessed features related to PCOS [<xref ref-type="bibr" rid="CR36">36</xref>]. These features of PCOS included measurement of ovulatory dysfunction, clinical or biochemical hyperandrogenism, and PCOM. No language restrictions were imposed. Studies that relied on self-reported or International Classification of Diseases (ICD) codes for PCOS status without the assessment of PCOS features were excluded. Exclusion criteria at the participant level included pregnant and lactating women, women with natural/surgical menopause, ovarian pathology, and women meeting the criteria for exclusion of other conditions in the diagnosis of PCOS. Additionally, women receiving contraceptive hormonal treatment within 3&#x000a0;months of assessment were excluded from the androgen analysis.</p><p id="Par49">Titles and abstracts were initially screened by a single reviewer (SK), and then full-text articles were retrieved and assessed in duplicate (SK and ADB) with any discrepancies resolved by a third reviewer (HJT). The corresponding and/or lead authors of the identified studies were contacted and requested to contribute to deidentified IPD for integration and analysis. For authors who did not respond, two reminder emails were sent.</p></sec><sec id="Sec5"><title>Data collection processes</title><p id="Par50">Data and relevant dictionaries were transferred to the ISO 27001-certified Secure File Transfer Protocol (SFTP) [<xref ref-type="bibr" rid="CR38">38</xref>] which restricts access and control to the authorized data custodian and researchers. The key variables collected aligned with the PCOS core outcomes set [<xref ref-type="bibr" rid="CR39">39</xref>] and included sociodemographic factors (age and race/ethnicity); generic outcomes (weight, height, body mass index (BMI)), metabolic outcomes (waist circumference (WC), hip circumference (HC), waist-to-hip ratio, homeostasis model assessment for insulin resistance (HOMA-IR), lipid profiles, blood pressure, and fasting blood glucose (FBG)); dermatological (hirsutism as measured by modified Ferriman-Gallwey (mFG score) and reproductive outcomes (androgen assays, menstrual cycle length, number of menstrual cycles per year, age of menarche, and PCOM features including antral follicle count (AFC) and ovarian volume (OV)). Any data discrepancies or concerns were discussed and resolved with the original study investigators.</p></sec><sec id="Sec6"><title>Risk of bias assessment</title><p id="Par51">We evaluated the risk of bias in the included studies providing IPD using the AXIS appraisal tool for cross-sectional studies [<xref ref-type="bibr" rid="CR40">40</xref>]. The appraisal was conducted by two independent reviewers (ADB and RRD), and any discrepancies were resolved through consensus. This tool consists of 20 items that assess various aspects such as the study&#x02019;s aim, design, sample size, outcome variable measurement, statistical methods, response rate, result consistency, discussion and conclusion, limitations, and ethical approval, with responses categorized as &#x0201c;yes,&#x0201d; &#x0201c;no,&#x0201d; or &#x0201c;don&#x02019;t know&#x0201d; [<xref ref-type="bibr" rid="CR41">41</xref>]. Overall quality was rated as low (score 1-7), medium (score 8-14), or high (score 15-20) [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec7"><title>Data harmonization and analysis</title><p id="Par52">Data synthesis involved rigorous procedures to ensure data integrity and harmonization across diverse datasets. All laboratory measurements were standardized to the International System of Units (SI) for consistency. Outliers were identified using scatter plots and box plots, applying a criterion where values exceeding&#x02009;&#x0003e;&#x02009;5 or&#x02009;&#x0003e;&#x02009;10 standard deviations were flagged [<xref ref-type="bibr" rid="CR42">42</xref>]. Invalid or implausible data points, such as diastolic blood pressure (DBP) surpassing systolic blood pressure (SBP), and height&#x02009;&#x0003c;&#x02009;120&#x000a0;cm were identified, based on consensus clinical judgment and predefined criteria. Definitions of outliers, invalid data points, and rules for variable harmonization were documented and collaboratively discussed with original study investigators to achieve consensus on data handling (Additional File 1: Table S4).</p><p id="Par53">For the harmonized definition of PCOS, we adhered to the International PCOS Guideline criteria, requiring two of three key features: OD, clinical or biochemical hyperandrogenism, and PCOM. The specific criteria for each feature were defined as follows:<list list-type="bullet"><list-item><p id="Par54">&#x025e6; OD: Menstrual cycles numbering fewer than eight or exceeding 17 per year, and/or cycle lengths shorter than 21&#x000a0;days or longer than 35&#x000a0;days.</p></list-item><list-item><p id="Par55">&#x025e6; Clinical hyperandrogenism: Defined by hirsutism quantified through the modified Ferriman-Gallwey (mFG) scoring system. We analyzed ethnic distribution patterns of mFG scores using descriptive statistics of means and medians. Subsequently, we standardized the data (mean&#x02009;=&#x02009;0, SD&#x02009;=&#x02009;1) and performed a <italic>k</italic>-means cluster analysis (<italic>k</italic>&#x02009;=&#x02009;2), with cluster determination guided by the average silhouette method, following our previously published methodology [<xref ref-type="bibr" rid="CR43">43</xref>].</p></list-item><list-item><p id="Par56">&#x025e6; Biochemical hyperandrogenism: Defined using study-specific 95th percentile cut-offs for first-line androgen tests (TT, FT, cFT, and FAI), supplemented by secondary markers (A4 and DHEAS) when first-line tests yielded negative results. This approach accounts for variations in assay methods and reference ranges across studies.</p></list-item><list-item><p id="Par57">&#x025e6; Polycystic ovarian morphology (PCOM): Given the considerable heterogeneity in imaging modalities, ultrasound approaches, and absence of individual participant data (IPD), harmonization of PCOM data proved unfeasible; thus, we relied on each study's original definitions and categorizations for this criterion.</p></list-item></list></p><p id="Par58">This study undertook a one-stage approach for analysis and only included women of reproductive age between 18 and 45&#x000a0;years. Continuous variables were reported as means with standard deviations (SD) or medians with interquartile ranges (IQR), as appropriate for the distribution of data. Categorical variables were reported as frequencies and proportions. Available case analysis was employed, and we did not opt to undertake multiple imputations for any missing data because they could not be random. Stata 18 software was used for data management and analysis.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Study characteristics and risk of bias</title><p id="Par59">The literature search identified 6507 publications, from which 1437 duplicates were removed. After screening the titles and abstracts, 342 studies underwent full-text review of which 313 studies were excluded (Additional File 1: Table S2). Finally, 29 studies met the eligibility criteria and their authors were contacted. Of these, the authors of 19 studies, encompassing 31,580 participants, did not respond. Of the 10 authors who responded, seven expressed willingness to collaborate and completed the data-sharing process, whereas three studies involving a combined total of 17,439 participants were unable to do so [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. Additionally, two ongoing studies were identified through other researchers, and two authors contributed more than one study from different populations. The entire P-PUP study dataset encompassed 12 population-based medically unbiased representative cohorts [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>] and 12,513 participants drawn from PCOS research groups spanning eight countries internationally (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A detailed assessment of the included studies&#x02019; methodological quality appraisal is presented in Additional File 1: Table S3. All of the included studies had a low risk of bias (high quality) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA IPD flow diagram for P-PUP study selection</p></caption><graphic xlink:href="12916_2025_4221_Fig1_HTML" id="MO1"/></fig></p><p id="Par60">Table <xref rid="Tab1" ref-type="table">1</xref> presents the characteristics of the final included studies. The entire P-PUP study dataset included studies from China (<italic>n</italic>&#x02009;=&#x02009;2; 4645 women) [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], Iran (<italic>n</italic>&#x02009;=&#x02009;3; 2517 women) [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], Italy (<italic>n</italic>&#x02009;=&#x02009;1; 519 women) [<xref ref-type="bibr" rid="CR50">50</xref>], Russia (<italic>n</italic>&#x02009;=&#x02009;1; 2695 women), South Korea (<italic>n</italic>&#x02009;=&#x02009;1; 499 women) [<xref ref-type="bibr" rid="CR26">26</xref>], Turkey (<italic>n</italic>&#x02009;=&#x02009;1; 392 women) [<xref ref-type="bibr" rid="CR51">51</xref>], the USA (<italic>n</italic>&#x02009;=&#x02009;2; 806 women) [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], and Nigeria (<italic>n</italic>&#x02009;=&#x02009;1; 440 women) [<xref ref-type="bibr" rid="CR47">47</xref>]. All studies were cross-sectional in design with sample sizes ranging from 392 to 3000.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of the included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Studies</th><th align="left">Country</th><th align="left">Study design</th><th align="left">Studies sample size</th><th align="left">Sample size (18&#x02013;45 years)</th><th align="left">Inclusion criteria</th><th align="left">Exclusion criteria</th><th align="left">Ovulatory dysfunction definition</th><th align="left">Clinical hyperandrogenism</th><th align="left">Biochemical hyperandrogenism definition for selected healthy controls</th><th align="left">Assay method</th><th align="left">&#x000a0;PCOM definition (approach and frequency)</th><th align="left">Quality score</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">China</td><td align="left">Cross-sectional</td><td align="left">2988</td><td align="left">3000</td><td align="left">Women aged 19&#x02013;45 years</td><td align="left">Pregnant women</td><td align="left">&#x0003c;8 cycle/year or cycle length &#x0003e;35 days</td><td align="left">mFG &#x02265;8 or acne</td><td align="left">Above 95<sup>th</sup> centile; TT: 3.08 nmol/L, FAI: 6.74, A4: 17.67 nmol/L.</td><td align="left">CLIA</td><td align="left">&#x02265;12 follicles (TVUS: 6&#x02013;9 or 6&#x02013;13 MHz and TAUS: 5&#x02013;6 or 3&#x02013;7 MHz)</td><td align="left">18</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">China</td><td align="left">Cross-sectional</td><td align="left">1645</td><td align="left">1369</td><td align="left">Women aged 18&#x02013;44.</td><td align="left">Women who were not residents in Chengdu, girls or women who in the previous 3 months took gonadal hormones or drugs which could affect ovarian function.</td><td align="left">Menstrual cycle &#x02265;35 days and for more than 3 months in a year ovulation is absent</td><td align="left">mFG &#x02265;6 with or without acne</td><td align="left">Two standard deviations above the normal (above 97.7<sup>th</sup> percentile) for FT &#x0003e;3.2 pg/mL (&#x0003e;0.0111 nmol/L).</td><td align="left">RIA</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS: 7 MHz and TAUS: 3.5 MHz)</td><td align="left">18</td></tr><tr><td align="left">Tehrani et al. 2011 [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">Iran</td><td align="left">Cross-sectional</td><td align="left">1000</td><td align="left">1000</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Pregnant, menopausal, and those who had undergone hysterectomy or bilateral oophorectomy</td><td align="left">Cycle length &#x0003e;35 days or P4 &#x0003c;4 ng/ml</td><td align="left">mFG &#x02265;8, acne, or alopecia</td><td align="left">Above 95<sup>th</sup> centile; TT: 0.89 ng/mL (3.09 nmol/L), FAI: 5.39, DHEAS: 179 &#x003bc;g/dL (4.85 &#x000b5;mol/L), A4: 2.9 ng/mL (10.12 nmol/L).</td><td align="left">EIA</td><td align="left">N/A</td><td align="left">19</td></tr><tr><td align="left">Tehrani et al. 2011 [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">Iran</td><td align="left">Cross-sectional</td><td align="left">915</td><td align="left">915</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Pregnant, menopausal, and those who had undergone hysterectomy or bilateral oophorectomy</td><td align="left">Cycle length &#x0003e;35 days.</td><td align="left">mFG &#x02265;8</td><td align="left">Above 95<sup>th</sup> centile; TT: 0.88 ng/mL (3.05 nmol/L), FAI: 5.47, DHEAS: 246 &#x003bc;g/dL (6.67 &#x000b5;mol/L), A4: 2.3 ng/mL (8.03 nmol/L).</td><td align="left">EIA</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS: 5 MHz and TAUS: 3.5 MHz)</td><td align="left">19</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">Iran</td><td align="left">Cross-sectional</td><td align="left">602</td><td align="left">602</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Pregnant, menopausal, and those who had undergone hysterectomy or bilateral oophorectomy</td><td align="left">Amenorrhea, cycle length &#x0003c;21 days or &#x0003e;35 days</td><td align="left">mFG &#x02265;8</td><td align="left">Above 95th centile; TT: 0.89 ng/mL (3.09 nmol/L), FAI: 5.39, DHEAS: 179 &#x003bc;g/dL (4.85 &#x000b5;mol/L), A4: 2.9 ng/mL (10.12 nmol/L).</td><td align="left">EIA</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS: 5 MHz and TAUS: 3.5 MHz)</td><td align="left">19</td></tr><tr><td align="left">Gambineri et al. 2013 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">Italy</td><td align="left">Cross-sectional</td><td align="left">519</td><td align="left">186</td><td align="left">Students aged 18&#x02013;19 years</td><td align="left">Those who refused to participate in the study</td><td align="left">&#x0003e;6 cycles with length &#x0003e;35 days/year or lack of menses for 3 consecutive months</td><td align="left">mFG &#x02265;8 or alopecia</td><td align="left">Above 97.5<sup>th</sup> percentile of the reference interval for TT: 0.45 ng/mL (1.57 nmol/L)</td><td align="left">LC-MS/MS</td><td align="left">N/A</td><td align="left">18</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">Nigeria</td><td align="left">Cross-sectional</td><td align="left">440</td><td align="left">440</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Women &#x0003c; 18 or &#x0003e; 45 years, pregnant, lactating, postmenopausal, and those who had undergone hysterectomy and/or bilateral oophorectomy.</td><td align="left">Cycle length &#x0003c;26 days or &#x0003e;35 days</td><td align="left">mFG &#x02265;6</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">&#x02265;20 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS: 4&#x02013;10 (6.7 and 8.5) MHz and TAUS: 1&#x02013;5 MHz)</td><td align="left">20</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">Russia</td><td align="left">Cross-sectional</td><td align="left">1134</td><td align="left">1550</td><td align="left">Women aged 18&#x02013;45 years who provided written informed consent</td><td align="left">Current pregnancy or lactation, history of hysterectomy and/or bilateral oophorectomy, endometrial ablation, and/or uterine artery embolization and noncompliance with all study procedures and requirements</td><td align="left">&#x0003c;21 or &#x0003e;35 days or &#x0003c;8 cycles per year</td><td align="left">mFG &#x02265;5</td><td align="left">Above 98<sup>th</sup> centile; TT: 73.9 ng/dL (2.56 nmol/L) for White Russians) and 41 ng/dL (1.42 nmol/L) for Asian Russians and Mixed Russians, FAI: 6.9 for White Russians and 2.9 for Asian Russians and Mixed Russians, DHEAS: 355 &#x003bc;g/dL (9.62 &#x000b5;mol/L) for all Russians.</td><td align="left">LC-MS/MS</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS: 5&#x02013;8 MHz and TAUS: 2.5&#x02013;5 MHz)</td><td align="left">17</td></tr><tr><td align="left">Kim et al. 2011 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">South Korea</td><td align="left">Cross-sectional</td><td align="left">499</td><td align="left">499</td><td align="left">Women aged 18&#x02013;40 years</td><td align="left">Pregnant women</td><td align="left">&#x0003c;8 cycles/year or cycle length &#x0003e;35 days or amenorrhea</td><td align="left">mFG &#x02265;6</td><td align="left">Above 95<sup>th</sup> centile; TT: 0.68 ng/mL (2.36 nmol/L), FAI: 5.36.</td><td align="left">RIA</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup> per ovary (TVUS and TAUS:5&#x02013;9 MHz)</td><td align="left">17</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">Turkey</td><td align="left">Cross-sectional</td><td align="left">392</td><td align="left">389</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Women &#x0003c;18 or &#x0003e;45 years, pregnant, postmenopausal, and those who had undergone hysterectomy or bilateral oophorectomy</td><td align="left">Cycle length &#x02264;23 days or &#x02265;35 days or P4 &#x02264;5 ng/ml</td><td align="left">mFG &#x02265;6</td><td align="left">Above 95<sup>th</sup> centile; TT: 54.7 ng/dL (1.9 nmol/L), FAI: 4.94, DHEAS: 3257.4 ng/mL (8.83 &#x000b5;mol/L), A4: 2.97 ng/mL (10.37 nmol/L)</td><td align="left">CLIA, RIA</td><td align="left">&#x02265;12 follicles and/or &#x02265;10 cm<sup>3</sup>per ovary (TVUS: 5&#x02013;9 and TAUS: 2&#x02013;7 MHz)</td><td align="left">17</td></tr><tr><td align="left">Knochenhauer et al. 1998 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">USA</td><td align="left">Cross-sectional</td><td align="left">411</td><td align="left">383</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Oophorectomised or those receiving hormonal treatment were excluded for circulating androgen levels.</td><td align="left">&#x02264;8 cycles/year or cycle &#x0003e;35 days</td><td align="left">mFG &#x02265;6</td><td align="left">Above 95<sup>th</sup> centile; TT: 84.7 ng/dl (2.94 nmol/L), cFT: 0.75 ng/dL (0.026 nmol/L), DHEAS: 2459 ng/ml (6.64 &#x000b5;mol/L), A4: 2496 pg/ml (8.73 nmol/L)</td><td align="left">RIA, RIA after extraction</td><td align="left">N/A</td><td align="left">17</td></tr><tr><td align="left">Azziz et al. 2004 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">USA</td><td align="left">Cross-sectional</td><td align="left">395</td><td align="left">388</td><td align="left">Women aged 18&#x02013;45 years</td><td align="left">Women &#x0003c;18 or &#x0003e;45 years, pregnant, menopausal, and those who had undergone hysterectomy or bilateral oophorectomy</td><td align="left">&#x02264;8 cycles/year or cycle length &#x0003c;26 or &#x0003e;35 days or day 22&#x02013;24 P4 &#x0003c;4 ng/ml</td><td align="left">mFG &#x02265;6</td><td align="left">Above 95<sup>th</sup> centile; TT: 84.7 ng/dl (2.94 nmol/L), cFT: 0.75 ng/dL (0.026 nmol/L), DHEAS: 2459 ng/ml (6.64 &#x000b5;mol/L), A4: 2496 pg/ml (8.73 nmol/L)</td><td align="left">RIA, RIA after extraction</td><td align="left">N/A</td><td align="left">17</td></tr></tbody></table><table-wrap-foot><p>The reported laboratory values were converted to the SI unit using the following conversion factors: for A4 3.49 from ng/mL to nmol/L and 0.00349 from pg/mL to nmol/L; for TT 3.47 from ng/mL to nmol/L and 0.0347 from ng/dL to nmol/L; for FT 0.003467 from pg/mL to nmol/L and 0.03467 from ng/dL to nmol/L; for DHEAS 0.00271 from ng/mL to &#x000b5;mol/L and 0.0271 &#x000b5;g/dL to &#x000b5;mol/L, N/A: Data not available, Quality was assessed using the AXIS tool and rated as high: 15&#x02013;20, medium: 8&#x02013;14, and low: 1&#x02013;7</p><p><italic>A4 </italic>androstenedione, <italic>FAI</italic> free androgen index, <italic>FT</italic> free testosterone, <italic>mFG score</italic> modified Ferriman-Gallwey score, <italic>TT</italic> total testosterone, <italic>DHEAS</italic> dehydroepiandrosterone sulfate, <italic>P4</italic> progesterone, <italic>CLIA </italic>chemiluminescence immunoassay, <italic>EIA</italic> enzyme immunoassay, <italic>LC-MS/MS</italic> liquid chromatography-tandem mass spectrometry, <italic>RIA</italic> radioimmunoassay, <italic>TVAS</italic> transvaginal ultrasound, <italic>TAUS</italic> transabdominal ultrasound</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Participant selection after data harmonization</title><p id="Par61">Of the total 12,513 participants in the P-PUP study, 2046 were excluded due to missing data on age (<italic>n</italic>&#x02009;=&#x02009;6), age&#x02009;&#x0003c;&#x02009;18&#x000a0;years (<italic>n</italic>&#x02009;=&#x02009;609), age&#x02009;&#x0003e;&#x02009;45 (<italic>n</italic>&#x02009;=&#x02009;1178), natural/surgical menopause (<italic>n</italic>&#x02009;=&#x02009;81), current pregnancy/lactation (<italic>n</italic>&#x02009;=&#x02009;40), and ovarian pathology (<italic>n</italic>&#x02009;=&#x02009;48). Additionally, 488 participants were excluded due to abnormal follicle-stimulating hormone (FSH&#x02009;&#x0003e;&#x02009;25&#x000a0;IU/L), prolactin (&#x0003e;&#x02009;67.2&#x000a0;&#x000b5;g/L), 17-hydroxyprogesterone (17-OHP&#x02009;&#x0003e;&#x02009;30&#x000a0;nmol/L), or thyroid-stimulating hormone (TSH&#x02009;&#x0003e;&#x02009;5 &#x000b5;U/mL) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Additional File 1: Table S4). A total number of 9979 participants was included in the final analysis following data harmonization. The predominant ethnicities represented in reproductive-age women were 40.1% Asian Han Chinese, 23.8% White Iranians, and 9.5% White Russians (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Flow chart for study participant selection. Note: TSH, prolactin, and 17-OHP were not consistently collected across the total populations in the studies, as some studies collect the data on women suspected of having PCOS</p></caption><graphic xlink:href="12916_2025_4221_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Ethnicity distribution of the study participants</p></caption><graphic xlink:href="12916_2025_4221_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>Assessment of ovulatory dysfunction</title><p id="Par62">All studies collected information on ovulatory dysfunction (OD) through the assessment of menstrual cycles, but the data collection methods were heterogeneous. Four studies collected data about OD in categorical form [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], with differing cut-offs: fewer than 21&#x000a0;days, 21&#x02013;35&#x000a0;days, or greater than 35&#x000a0;days [<xref ref-type="bibr" rid="CR52">52</xref>]; 35&#x000a0;days or less or greater than 35&#x000a0;days [<xref ref-type="bibr" rid="CR56">56</xref>]; less than 26&#x000a0;days and greater than 35&#x000a0;days [<xref ref-type="bibr" rid="CR55">55</xref>]; and another reported it as a binary with regular (21&#x02013;35&#x000a0;days) or irregular (fewer than 21&#x000a0;days, greater than 35&#x000a0;days or irregular bleeding) [<xref ref-type="bibr" rid="CR48">48</xref>]. Six studies collected actual menstrual cycle length [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], seven studies collected the number of menstrual cycles per year [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], and one study recorded the minimum and maximum menstrual cycle lengths, in addition to the overall menstrual cycle length [<xref ref-type="bibr" rid="CR31">31</xref>]. One study also reported minimum and maximum cycle lengths and cycle numbers per year in addition to the categorical menstrual cycle status, with nearly 60% missing data [<xref ref-type="bibr" rid="CR48">48</xref>]. Except for one study [<xref ref-type="bibr" rid="CR31">31</xref>] which had 4% (62/1550) missing data, the remaining studies provided complete data on OD (Additional file 1: Table S5).</p><p id="Par63">The definitions of OD varied across studies and are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Most studies defined OD based on menstrual cycle length or the number of menstrual cycles per year, with some including progesterone levels to further assess ovulation status. OD was most commonly defined by using an upper limit of menstrual cycle length greater than 35&#x000a0;days [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], with another study using a threshold of greater than 34&#x000a0;days [<xref ref-type="bibr" rid="CR51">51</xref>]. The lower limit for menstrual cycle length also varied, with three studies using less than 21&#x000a0;days [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], one study using less than 24&#x000a0;days [<xref ref-type="bibr" rid="CR51">51</xref>], one using less than 26&#x000a0;days [<xref ref-type="bibr" rid="CR55">55</xref>], and another one using less than 25&#x000a0;days [<xref ref-type="bibr" rid="CR47">47</xref>]. For the number of menstrual cycles per year, four studies defined OD as less than eight menstrual cycles per year [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], while two studies used the cut-off of fewer than nine cycles per year [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Additionally, three studies incorporated a lack of menses for three consecutive months as part of their OD definition [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Mid-luteal progesterone level was utilized by three studies as part of their assessment of OD [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. The reported prevalence of OD in the included studies ranged from 9.2 to 31.9%, with an overall aggregated prevalence of 18.2%. For data harmonization, we defined OD as fewer than eight or more than 17 menstrual cycles per year and/or a menstrual cycle length of less than 21&#x000a0;days or greater than 35&#x000a0;days, in alignment with the 2023 International PCOS Guidelines [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Based on this definition, the prevalence of OD across the included studies ranged from 3.7 to 31.9%, with an overall prevalence of 15.3% (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Prevalence of ovulatory dysfunction</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Studies</th><th align="left" colspan="4">Prevalence</th></tr><tr><th align="left" colspan="2">Original data <italic>n</italic> (%)</th><th align="left" colspan="2">Harmonized data <italic>n</italic> (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">421 (14.0)</td><td align="left">2579 (86.0)</td><td align="left">519 (17.8)</td><td align="left">2400 (82.2)</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">436 (31.9)</td><td align="left">932 (68.1)</td><td align="left">431 (31.9)</td><td align="left">919 (68.1)</td></tr><tr><td align="left">Tehrani et al. 2011a [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">140 (14.0)</td><td align="left">857 (86.0)</td><td align="left">114 (11.7)</td><td align="left">&#x000a0;861 (88.3)</td></tr><tr><td align="left">Tehrani et al. 2011b [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">170 (18.6)</td><td align="left">745 (81.4)</td><td align="left">146 (19.2)</td><td align="left">614 (80.8)</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">72 (12.0)</td><td align="left">529 (88.0)</td><td align="left">67 (13.4)</td><td align="left">432 (86.6)</td></tr><tr><td align="left">Gambineri et al. 2013<sup>a</sup> [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">N/R</td><td align="left">N/R</td><td align="left">13 (7.1)</td><td align="left">169 (92.9)</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">67 (15.3)</td><td align="left">371 (84.7)</td><td align="left">15 (3.7)</td><td align="left">394 (96.3)</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">342 (24.4)</td><td align="left">1061 (75.6)</td><td align="left">81 (6.3)</td><td align="left">1209 (93.7)</td></tr><tr><td align="left">Kim et al. 2011 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">70 (14.1)</td><td align="left">427 (85.9)</td><td align="left">26 (6.2)</td><td align="left">392 (93.8)</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">60 (15.4)</td><td align="left">329 (84.6)</td><td align="left">17 (4.4)</td><td align="left">370 (95.6)</td></tr><tr><td align="left">Knochenhauer et al. 1998 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">33 (9.2)</td><td align="left">325 (90.8)</td><td align="left">33 (9.2)</td><td align="left">325 (90.8)</td></tr><tr><td align="left">Azziz et al. 2004 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">75 (20.5)</td><td align="left">291 (79.5)</td><td align="left">52 (14.2)</td><td align="left">313 (85.8)</td></tr><tr><td align="left">Overall</td><td align="left">1886 (18.2)</td><td align="left">8446 (81.8)</td><td align="left">1514 (15.3)</td><td align="left">8398 (84.7)</td></tr></tbody></table><table-wrap-foot><p><italic>N/R</italic> not reported</p><p><sup>a</sup>very small sample size. For data harmonization, we defined OD as fewer than eight or more than 17 menstrual cycles per year and/or a menstrual cycle length of less than 21 days or greater than 35 days, in alignment with the 2023 International PCOS Guidelines</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Assessment of clinical hyperandrogenism</title><p id="Par64">All included studies assessed clinical hyperandrogenism, using hirsutism as a primary criterion [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. Hirsutism was assessed directly by a health professional, including gynecologists, midwives, physicians, nurses, endocrinologists, and general practitioners using the mFG score. Hirsutism was defined by an mFG score of 6 or higher in six studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], 8 or higher in five studies [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>], and 5 or higher in one study [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par65">All studies reported acne [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], with nine providing IPD [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], and three incorporating acne into their definition of clinical hyperandrogenism [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. One study employed the Burke-Cunliffe acne grading method, assessed by a physician [<xref ref-type="bibr" rid="CR50">50</xref>]; six studies employed the standard acne lesion assessment of the face, back, and chest, assessed by gynecologists, midwives, physicians, and general practitioners [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]; two studies mentioned that no specific acne scoring system was used, with assessments conducted by nurses [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], while another two studies did not provide details on the acne scoring tools used, with assessments conducted by physicians [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. One study used self-reported acne without a specific scoring system [<xref ref-type="bibr" rid="CR26">26</xref>]. Among studies that included acne in their clinical hyperandrogenism definition, a score of two or higher was used in one study [<xref ref-type="bibr" rid="CR52">52</xref>], six or higher in another [<xref ref-type="bibr" rid="CR54">54</xref>], and the cut-off was not specified in one study [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par66">Six studies reported on the presence of female pattern hair loss (FPHL) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], with four providing IPD [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], and two incorporated FPHL into their definition of clinical hyperandrogenism [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. The presence of FPHL was assessed by gynecologists, physicians, nurses, and general practitioners using the Ludwig scale in three studies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], while three other studies provided no details on the FPHL assessment tool used [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. FPHL was reported in a categorized form in two studies with no cut-offs provided [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par67">For data harmonization, we defined clinical hyperandrogenism using hirsutism only in alignment with the 2023 International PCOS Guidelines which highlights hirsutism as the strongest predictor of hyperandrogenism. We used ethnicity-specific mFG score cut-offs derived from <italic>k</italic>-means (<italic>k</italic>&#x02009;=&#x02009;2) cluster analysis in our recent publication [<xref ref-type="bibr" rid="CR43">43</xref>]. The thresholds were set at mFG score&#x02009;&#x02265;&#x02009;8 for Iranians,&#x02009;&#x02265;&#x02009;7 for White Italians and Black Africans,&#x02009;&#x02265;&#x02009;5 for Asian Han Chinese, White Russians, Turkish, and Black Americans, and&#x02009;&#x02265;&#x02009;4 for White Americans, Asian Koreans, Asian Russians, and Mixed Russians [<xref ref-type="bibr" rid="CR43">43</xref>]. Based on these cut-offs, the prevalence of clinical hyperandrogenism ranged from 8.1 to 34.2% in individual included studies, with an overall aggregate prevalence of 14.2% (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Prevalence of clinical hyperandrogenism</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Studies</th><th align="left" colspan="4">Prevalence</th></tr><tr><th align="left" colspan="2">Original data <italic>n</italic> (%)</th><th align="left" colspan="2">Harmonized data<italic> n</italic> (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">325 (10.8)</td><td align="left">2675 (89.2)</td><td align="left">304 (10.4)</td><td align="left">2615 (89.6)</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">175 (12.8)</td><td align="left">1192 (87.2)</td><td align="left">205 (16.9)</td><td align="left">1009 (83.1)</td></tr><tr><td align="left">Tehrani et al. 2011a [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">234 (23.5)</td><td align="left">763 (76.5)</td><td align="left">168 (17.2)</td><td align="left">807 (82.8)</td></tr><tr><td align="left">Tehrani et al. 2011b [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">200 (21.9)</td><td align="left">715 (78.1)</td><td align="left">170 (22.4)</td><td align="left">590 (77.6)</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">171 (28.4)</td><td align="left">430 (71.6)</td><td align="left">133 (26.7)</td><td align="left">366 (73.3)</td></tr><tr><td align="left">Gambineri et al. 2013<sup>a</sup> [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">40 (21.5)</td><td align="left">146 (78.5)</td><td align="left">62 (34.2)</td><td align="left">119 (65.8)</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">43 (9.8)</td><td align="left">395 (90.2)</td><td align="left">28 (6.9)</td><td align="left">377 (93.1)</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">103 (7.3)</td><td align="left">1298 (92.7)</td><td align="left">105 (8.1)</td><td align="left">1183 (91.6)</td></tr><tr><td align="left">Kim et al. 2011 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">49 (9.8)</td><td align="left">449 (90.2)</td><td align="left">74 (15.3)</td><td align="left">409 (84.7)</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">40 (10.3)</td><td align="left">349 (89.7)</td><td align="left">65 (16.8)</td><td align="left">322 (83.2)</td></tr><tr><td align="left">Knochenhauer et al. 1998 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">30 (8.4)</td><td align="left">328 (91.6)</td><td align="left">41 (11.9)</td><td align="left">303 (88.1)</td></tr><tr><td align="left">Azziz et al. 2004 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">25 (6.8)</td><td align="left">341 (93.2)</td><td align="left">41 (11.4)</td><td align="left">318 (88.6)</td></tr><tr><td align="left">Overall</td><td align="left">1435 (13.7)</td><td align="left">9081 (86.3)</td><td align="left">1396 (14.2)</td><td align="left">8418 (85.8)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>very small sample size. For data harmonization, we defined clinical hyperandrogenism using ethnicity-specific modified Ferriman-Gallwey (mFG) score cut-offs derived from <italic>k</italic>-means (<italic>k&#x000a0;</italic>= 2) cluster analysis with the thresholds set at mFG score &#x02265;8 for White Iranians, &#x02265;7 for White Italians and Black Africans, &#x02265;5 for Asian Han Chinese, White Russians, Turkish, and Black Americans, and &#x02265;4 for White Americans, Asian Koreans, Asian Russians, and Mixed Russians [<xref ref-type="bibr" rid="CR43">43</xref>]</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Assessment of biochemical hyperandrogenism</title><p id="Par68">Biochemical hyperandrogenism was assessed in all included studies except for one study done in Nigeria [<xref ref-type="bibr" rid="CR47">47</xref>]. Seven studies assessed all participants [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], three studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] assessed selective subgroups, and the remaining one study collected blood samples from a random half of the population [<xref ref-type="bibr" rid="CR52">52</xref>]. Among the studies that assessed androgen levels in selective subgroups, Tehrani et al. assessed only participants with either hirsutism (mFG score&#x02009;&#x02265;&#x02009;8) or menstrual disorder (26% of the sample, 260/1000) [<xref ref-type="bibr" rid="CR54">54</xref>]; Azziz et al. assessed only participants with menstrual dysfunction (48.7% of the sample, 189/388) [<xref ref-type="bibr" rid="CR55">55</xref>]; and Kim et al. assessed participants who consented to provide blood samples (32.1% of the sample, 160/499) [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par69">Of the included studies, 11 reported total testosterone (TT) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], seven reported calculated free androgen index (FAI) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>], eight reported androstenedione (A4) [<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], and nine reported dehydroepiandrosterone sulfate (DHEAS) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. The assay method used included enzyme immunoassay (EIA) [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>], liquid-chromatography tandem mass spectrometry (LC&#x02013;MS/MS) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], chemiluminescent immunoassay (CLIA) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], radioimmunoassay (RIA) after extraction [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], and RIA [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Three studies reported free testosterone (FT) [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]: two reported calculated FT (cFT), derived from TT measured by an in-house RIA after serum extraction and SHBG binding activity by equilibrium dialysis using Sephadex G-25 and [3H]T as the ligand, and approximations for binding to albumin [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>], while one study reported directly measured FT utilizing RIA [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par70">Biochemical hyperandrogenism was defined using the selected control subgroups as above 95th percentile in eight studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>], above 97.5th percentile in one study [<xref ref-type="bibr" rid="CR50">50</xref>], above 97.7th percentile (equivalent to 2 standard deviations above the mean in normally distributed data) in another study [<xref ref-type="bibr" rid="CR48">48</xref>], and above 98th percentile in one study [<xref ref-type="bibr" rid="CR31">31</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The prevalence of biochemical hyperandrogenism varied widely across studies, ranging from 5.6 to 30.0%, with an overall prevalence of 17.4%. In this study, we adapted the 95th percentile cut-off specific to each study for harmonization to account for variations in assay methods and reference ranges across studies. We used first-line tests (TT, FT, cFT, and FAI) and second-line tests (A4 and DHEAS) when first-line tests were negative, as per the 2023 International PCOS Guidelines. This approach revealed a biochemical hyperandrogenism prevalence ranging from 11.0 to 30.3%, with an overall prevalence of 20.4%. The overall prevalence remained nearly the same at 20.2% when studies assessing selective subgroups of populations were excluded (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Prevalence of biochemical hyperandrogenism</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Studies</th><th align="left" colspan="4">Prevalence</th><th align="left" rowspan="3">Harmonized androgen cut-offs (95<sup>th</sup> percentile)</th></tr><tr><th align="left" colspan="2">Original data <italic>n</italic> (%)</th><th align="left" colspan="2">Harmonized data <italic>n</italic> (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">268 (17.6)</td><td align="left">1258 (82.4)</td><td align="left">250 (17.3)</td><td align="left">1197 (82.7)</td><td align="left">TT: 3.08 nmol/L, FAI: 6.74, and A4: 17.67 nmol/L</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">77 (5.6)</td><td align="left">1293 (94.4)</td><td align="left">164 (12.1)</td><td align="left">1187 (87.9)</td><td align="left">TT: 2.95 nmol/L and FT: 3.2 pg/mL (0.010366 nmol/L)</td></tr><tr><td align="left">Tehrani et al. 2011a<sup>a</sup> [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">71 (28.5)</td><td align="left">178 (71.5)</td><td align="left">64 (27.8)</td><td align="left">166 (72.2)</td><td align="left">TT: 0.89 ng/mL (3.09 nmol/L), FAI: 5.39, DHEAS: 179 &#x003bc;g/dL (4.85 &#x003bc;mol/L), A4: 2.9 ng/mL (10.12 nmol/L)</td></tr><tr><td align="left">Tehrani et al. 2011b [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">169 (21.3)</td><td align="left">623 (78.7)</td><td align="left">169 (26.0)</td><td align="left">482 (74.0)</td><td align="left">TT: 0.88 ng/mL (3.05 nmol/L), FAI: 5.47, DHEAS: 246 &#x003bc;g/dL (6.67 &#x000b5;mol/L), A4: 2.3 ng/mL (8.03 nmol/L)</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">160 (30.0)</td><td align="left">372 (70.0)</td><td align="left">133 (30.3)</td><td align="left">306 (69.7)</td><td align="left">TT: 0.89 ng/mL (3.09 nmol/L), FAI: 5.39, DHEAS: 179 &#x003bc;g/dL (4.85 &#x003bc;mol/L), A4: 2.9 ng/mL (10.12 nmol/L)</td></tr><tr><td align="left">Gambineri et al. 2013<sup>b</sup> [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">N/R</td><td align="left">N/R</td><td align="left">20 (11.0)</td><td align="left">161 (89.0)</td><td align="left">TT: 1.66 nmol/L and A4: 5.78 nmol/L</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">232 (19.7)</td><td align="left">947 (80.4)</td><td align="left">313 (29.0)</td><td align="left">766 (71.0)</td><td align="left">TT: 54.77 ng/dL (1.90 nmol/L) for White Russians), 34.33 ng/dL (1.19 nmol/L) for Asian Russians, and 43.78 ng/dL (1.52 nmol/L) for Mixed Russians, FAI: 4.73 for White Russians, 2.11 for Asian Russians, and 2.97 for Mixed Russians, DHEAS: 314.6 &#x003bc;g/dl (8.53 &#x000b5;mol/L) for all Russians.</td></tr><tr><td align="left">Kim et al. 2011<sup>a</sup> [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">16 (10.0)</td><td align="left">144 (90.0)</td><td align="left">20 (12.8)</td><td align="left">136 (87.2)</td><td align="left">TT: 0.68 ng/mL (2.36 nmol/L), FAI: 5.36, DHEAS: 10.55 &#x000b5;mol/L</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">68 (18.2)</td><td align="left">305 (81.8)</td><td align="left">67 (18.2)</td><td align="left">302 (81.8)</td><td align="left">TT: 54.7 ng/dL (1.9 nmol/L), FAI: 4.94, DHEAS: 3257.4 ng/mL (8.83 &#x000b5;mol/L), A4: 2.97 ng/mL (10.37 nmol/L)</td></tr><tr><td align="left">Knochenhauer et al. 1998 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">37 (20.4)</td><td align="left">144 (79.6)</td><td align="left">37 (20.4)</td><td align="left">144 (79.6)</td><td align="left">TT: 84.7 ng/dl (2.94 nmol/L), cFT: 0.75 ng/dL (0.026 nmol/L), DHEAS: 2459 ng/ml (6.64 &#x000b5;mol/L), A4: 2496 pg/ml (8.73 nmol/L)</td></tr><tr><td align="left">Azziz et al. 2004<sup>a</sup> [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">30 (26.6)</td><td align="left">83 (73.4)</td><td align="left">30 (26.8)</td><td align="left">82 (73.2)</td><td align="left">TT: 84.7 ng/dl (2.94 nmol/L), cFT: 0.75 ng/dL (0.026 nmol/L), DHEAS: 2459 ng/ml (6.64 &#x003bc;mol/L), A4: 2496 pg/ml (8.73 nmol/L)</td></tr><tr><td align="left">Overall</td><td align="left">1128 (17.4)</td><td align="left">5348 (82.6)</td><td align="left">1267 (20.4)</td><td align="left">4929 (79.7)</td><td align="left">n/a</td></tr></tbody></table><table-wrap-foot><p><italic>N/A</italic> data not available, <italic>N/R</italic> not reported, <italic>n/a</italic> not applicable</p><p><sup>a</sup>Studies assessing a selective group of participants for biochemical hyperandrogenism</p><p><sup>b</sup>very small sample size. We calculated the 95<sup>th</sup> percentile from selected healthy controls for TT in Zhuang et al. (2014), A4 in Gambineri et al. (2013), and DHEAS in Kim et al. (2011); the original authors did not use these androgens in their classifications. Additionally, we calculated the 95<sup>th</sup> percentile for TT in Gambineri et al. (2013). The reported laboratory values were converted to the SI unit using the following conversion factors: for A4 3.49 from ng/mL to nmol/L and 0.00349 from pg/mL to nmol/L; for TT 3.47 from ng/mL to nmol/L and 0.0347 from ng/dL to nmol/L; for FT 0.003467 from pg/mL to nmol/L and 0.03467 from ng/dL to nmol/L; for DHEAS 0.00271 ng/mL to &#x000b5;mol/L and 0.0271 &#x000b5;g/dL to &#x000b5;mol/L. For data harmonization, we utilized the 95<sup>th</sup> percentile cut-off specific to each individual study population, applying first-line tests (TT, FT, and FAI) and incorporating A4 and DHEAS when first-line tests were negative, in accordance with the 2023 International PCOS Guidelines</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>Assessment of polycystic ovary morphology (PCOM)</title><p id="Par71">Eight included studies assessed all participants for PCOM. One study provided PCOM as a binary variable [<xref ref-type="bibr" rid="CR49">49</xref>], OV data was provided by six studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], while AFC was provided by seven studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. The imaging modalities used included transvaginal ultrasound with a band frequency ranging from 5 to 13&#x000a0;MHz, and transabdominal ultrasound with a band frequency ranging from 1 to 9&#x000a0;MHz. Additionally, transrectal ultrasound was utilized in two studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Unfortunately, the IPD in the included studies did not specify the ultrasound approach, either transvaginal, transabdominal, or transrectal.</p><p id="Par72">Except for Makwe et al. which defined PCOM as having an AFC count of&#x02009;&#x02265;&#x02009;20 and/or OV&#x02009;&#x02265;&#x02009;10cm<sup>3</sup> [<xref ref-type="bibr" rid="CR47">47</xref>], all other included studies used older criteria, defining PCOM as having an AFC count of&#x02009;&#x02265;&#x02009;12 and/or OV&#x02009;&#x02265;&#x02009;10cm<sup>3</sup> [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. The reported prevalence of PCOM varied widely across studies, ranging from 6.6 to 39.9%, with an overall prevalence of 19.2% (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). Due to the heterogeneity in imaging modalities, ultrasound approaches, and lack of IPD, data harmonization for PCOM was not feasible, and thus we relied on each study&#x02019;s original definitions and categorization.
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Prevalence of polycystic ovary morphology (PCOM)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Studies</th><th align="left" colspan="4">Prevalence</th></tr><tr><th align="left" colspan="2">Original data <italic>n </italic>(%)</th><th align="left" colspan="2">Harmonized data <italic>n</italic> (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">567 (19.4)</td><td align="left">2348 (80.6)</td><td align="left">546 (19.2)</td><td align="left">2290 (80.8)</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">91 (6.6)</td><td align="left">1278 (93.4)</td><td align="left">90 (6.7)</td><td align="left">1260 (93.3)</td></tr><tr><td align="left">Tehrani et al. 2011a [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Tehrani et al. 2011b [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">156 (17.0)</td><td align="left">759 (83.0)</td><td align="left">132 (17.4)</td><td align="left">628 (82.6)</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">118 (19.6)</td><td align="left">483 (80.4)</td><td align="left">99 (19.8)</td><td align="left">400 (80.2)</td></tr><tr><td align="left">Gambineri et al. 2013 [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">151 (34.5)</td><td align="left">287 (65.5)</td><td align="left">139 (34.0)</td><td align="left">270 (66.0)</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">285 (20.5)</td><td align="left">1104 (79.5)</td><td align="left">266 (20.8)</td><td align="left">1013 (79.2)</td></tr><tr><td align="left">Kim et al. 2011 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">91 (23.6)</td><td align="left">295 (76.4)</td><td align="left">89 (23.9)</td><td align="left">283 (76.1)</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">155 (39.9)</td><td align="left">234 (60.1)</td><td align="left">154 (39.8)</td><td align="left">233 (60.2)</td></tr><tr><td align="left">Knochenhauer et al. 1998 [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Azziz et al. 2004 [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">Overall</td><td align="left">1614 (19.2)</td><td align="left">6788 (80.8)</td><td align="left">1515 (19.2)</td><td align="left">6377 (80.8)</td></tr></tbody></table><table-wrap-foot><p>For data harmonization, we used the original authors&#x02019; categorization for PCOM, which was defined as an antral follicle count (AFC) &#x02265;12 follicles and/or ovarian volume (OV) &#x02265;10 cm<sup>3</sup>, except for Makwe et al. (2023), where PCOM was defined as AFC &#x02265;20 follicles and/or OV &#x02265;10 cm<sup>3</sup></p><p><italic>PCOM </italic>polycystic ovary morphology, <italic>N/A</italic> data not available</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Prevalence of polycystic ovary syndrome (PCOS)</title><p id="Par73">Of the included study, eight defined PCOS using the Rotterdam criteria [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>], while the remaining four used the National Institutes of Health (NIH 1990) criteria and did not include ultrasound data for PCOM [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR54">54</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]. The reported prevalence ranged from 3.3 to 19.8%, with an overall prevalence of 11.7% using each study&#x02019;s original definition. For data harmonization, we defined PCOS by applying the International PCOS Guidelines criteria, requiring two out of three key features: OD, hyperandrogenism, and PCOM. We defined OD as fewer than eight or more than 17 menstrual cycles per year and/or a menstrual cycle length of less than 21&#x000a0;days or greater than 35&#x000a0;days; we defined hyperandrogenism as either clinical (limited to ethnicity-specific hirsutism scores) or biochemical (using study-specific 95th percentile cut-offs for first-line androgen tests, supplemented by secondary markers when first-line tests were negative), in accordance with the 2023 International PCOS Guidelines recommendations. Post harmonization, the prevalence of PCOS ranged from 3.3 to 18.3%, with an overall prevalence of 11.0% (Table&#x000a0;<xref rid="Tab6" ref-type="table">6</xref>).
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Prevalence of polycystic ovary syndrome (PCOS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Studies</th><th align="left" colspan="4">Prevalence</th></tr><tr><th align="left" colspan="2">Original data <italic>n</italic> (%)</th><th align="left" colspan="2">Harmonized data <italic>n</italic> (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">Zhao et al. 2011 [<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">346 (11.5)</td><td align="left">2654 (88.5)</td><td align="left">360 (12.3)</td><td align="left">2559 (87.7)</td></tr><tr><td align="left">Zhuang et al. 2014 [<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">153 (11.2)</td><td align="left">1217 (88.8)</td><td align="left">169 (12.5)</td><td align="left">1182 (875)</td></tr><tr><td align="left">Tehrani et al. 2011a<sup>a</sup> [<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">86 (8.6)</td><td align="left">911 (91.4)</td><td align="left">63 (6.5)</td><td align="left">912 (93.5)</td></tr><tr><td align="left">Tehrani et al. 2011b [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">139 (15.2)</td><td align="left">776 (84.8)</td><td align="left">120 (15.8)</td><td align="left">640 (84.2)</td></tr><tr><td align="left">Tehrani et al. 2014 [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">84 (14.0)</td><td align="left">517 (86.0)</td><td align="left">73 (14.6)</td><td align="left">426 (85.4)</td></tr><tr><td align="left">Gambineri et al. 2013<sup>a</sup> [<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">N/R</td><td align="left">N/R</td><td align="left">6 (3.3)</td><td align="left">176 (96.7)</td></tr><tr><td align="left">Makwe et al. 2023 [<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">38 (8.7)</td><td align="left">400 (91.3)</td><td align="left">15 (3.7)</td><td align="left">394 (96.3)</td></tr><tr><td align="left">Suturina et al. 2022 [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">168 (14.4)</td><td align="left">1001 (85.6)</td><td align="left">151 (11.7)</td><td align="left">1140 (88.3)</td></tr><tr><td align="left">Kim et al. 2011 [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">57 (11.4)</td><td align="left">441 (88.6)</td><td align="left">43 (8.9)</td><td align="left">440 (91.1)</td></tr><tr><td align="left">Yildiz et al. 2012 [<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">77 (19.8)</td><td align="left">312 (80.2)</td><td align="left">71 (18.3)</td><td align="left">316 (81.7)</td></tr><tr><td align="left">Knochenhauer et al. 1998<sup>a</sup> [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">12 (3.3)</td><td align="left">346 (96.7)</td><td align="left">12 (3.3)</td><td align="left">346 (96.7)</td></tr><tr><td align="left">Azziz et al. 2004* [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">19 (5.2)</td><td align="left">347 (94.8)</td><td align="left">16 (4.4)</td><td align="left">349 (95.6)</td></tr><tr><td align="left">Overall</td><td align="left">1179 (11.7)</td><td align="left">8922 (88.3)</td><td align="left">1099 (11.0)</td><td align="left">8880 (89.0)</td></tr></tbody></table><table-wrap-foot><p><italic>PCOS </italic>polycystic ovary syndrome. N/R: not reported</p><p><sup>a</sup>NIH criteria. For data harmonization, we defined PCOS using two out of the three key features&#x02014;OD, hyperandrogenism (clinically defined based on hirsutism and/or biochemically), and PCOM&#x02014;in studies reporting all three key features, and OD and hyperandrogenism in studies where PCOM was not reported. Secondary causes that may mimic PCOS, such as hyperprolactinemia, thyroid dysfunction, and non-classical adrenal hyperplasia, were excluded</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par74">The P-PUP study represents the first international IPD-based meta-analysis involving unselected (medically unbiased) women from the general population, assessed for PCOS features, offering a unique and diverse cohort to explore PCOS characteristics across heterogeneous populations. This comprehensive dataset includes a large sample size of 9979 women aged 18&#x02013;45&#x000a0;years from 11 primary ethnicities, eight countries and four continents. Our analysis revealed significant heterogeneity in data collection methods and the definitions used for PCOS diagnostic features, particularly in the assessment of ovulatory dysfunction. This variability contributed to a wide range of reported prevalence of PCOS across original studies, from 3.3 to 19.8% (11.7% overall). After data harmonization, the PCOS prevalence ranged from 3.3 to 18.3%, with an overall prevalence of 11.0%.</p><p id="Par75">Ovulatory dysfunction (OD) is a key component in the International Guidelines PCOS diagnostic criteria, focused on menstrual cyclicity, and irregular cycle length and number per year. The International PCOS Guidelines [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>], defined irregular cycles as&#x02009;&#x0003e;&#x02009;90&#x000a0;days for any one cycle in women 1-year post menarche,&#x02009;&#x0003c;&#x02009;21 or&#x02009;&#x0003e;&#x02009;45&#x000a0;days in women one to less than 3&#x000a0;years post menarche,&#x02009;&#x0003c;&#x02009;21 or&#x02009;&#x0003e;&#x02009;35&#x000a0;days or&#x02009;&#x0003c;&#x02009;8 cycles per year in women 3&#x000a0;years post-menarche to perimenopause, while acknowledging the need for further research [<xref ref-type="bibr" rid="CR57">57</xref>]. We identified significant variations in menstrual cycle data collection, especially prior to the International PCOS Guidelines. Categorical and continuous data was collected, including average cycle length in days, average cycle number per year, minimum and maximum cycle length and cycle number per year. OD cut-offs were variable across studies. Here, we harmonized OD data aligned with Guideline recommendations, reporting a prevalence of 3.7% to 31.9% or 15.5% overall. Future studies should collect standardized continuous data on cycle length (in days) and cycle number per year, with clear explanations of cycle length as the number of days from the first day of one period to the first day of the next, to limit confusion with the duration of menstrual bleeding. While acknowledging the inherent variability of cycles in PCOS and limitations of self-reported data for large-scale epidemiology studies, standardized data collection and definitions would substantially minimize error while ensuring consistency and comparability across studies. The International PCOS Guideline&#x02019;s OD cut-offs were derived from the 95th percentile of menstrual cycle duration, based on variable control populations which likely included women with PCOS [<xref ref-type="bibr" rid="CR58">58</xref>]. Using this percentile as a diagnostic cut-off, particularly when it is not linked with clinical outcomes, including anthropometric outcomes (weight, waist-hip circumference, BMI), reproductive outcomes (androgens, ovulation frequency, pregnancy complications), and cardiometabolic (insulin resistance, lipid profiles, blood pressure, fasting glucose), represents a crude and overly simplistic approach [<xref ref-type="bibr" rid="CR58">58</xref>]. Moving forward, applying advanced analytics including cluster analysis to define cut-offs based on well-defined unselected populations and clinical correlates such as association with other PCOS features or with long-term outcomes is a research priority captured in the International PCOS Research Road Map [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par76">Hyperandrogenism is an essential PCOS diagnostic feature and manifests clinically as hirsutism, acne and androgenic alopecia. Acne and androgenic alopecia are relatively nonspecific markers of hyperandrogenism, particularly in PCOS [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. While validated scoring systems exist for acne and androgenic alopecia, these are not universally agreed upon for PCOS due to limited research in PCOS populations, ethnic variations, and clinical contexts. In included original studies, acne and alopecia were inconsistently reported, with variable tools and definitions. In contrast, hirsutism is strongly correlated with biochemical hyperandrogenism and is the most reliable clinical sign of hyperandrogenism in PCOS [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The modified Ferriman-Gallwey (mFG) visual scale is Guideline recommended [<xref ref-type="bibr" rid="CR62">62</xref>] and was used in all included original studies. Historically, a cut-off mFG score of&#x02009;&#x02265;&#x02009;8 defined hirsutism in PCOS, based on a misinterpretation of original Ferriman and Gallwey data at the 95th percentile of a predominantly white population [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. In P-PUP IPD we established ethnicity-specific mFG cut-offs via <italic>k</italic>-means cluster analysis, with cut-offs ranging between 4&#x02013;6 for the majority of populations [<xref ref-type="bibr" rid="CR43">43</xref>]. This aligns with the International PCOS Guidelines recommendations for an mFG score of 4&#x02013;6 to diagnose hirsutism [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Clinical hyperandrogenism ranged from 6.8 to 28.4% (13.7% overall) in original studies with variable mFG cut-offs and use of acne and alopecia. With cluster analysis cut-offs and data harmonization, we report a prevalence of 8.1% to 34.2% (14.2% overall) and aligned to Guidelines, cluster-defined mFG cut-offs are recommended.</p><p id="Par77">Biochemical hyperandrogenism in PCOS focuses on elevated free testosterone, which may be measured directly or calculated primarily through FAI and cFT. Our recent systematic review and meta-analysis informed the International PCOS Guidelines recommendation to use TT and FT as a first-line laboratory test for biochemical hyperandrogenism [<xref ref-type="bibr" rid="CR65">65</xref>] using LC&#x02013;MS/MS methods with the best accuracy [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. In the P-PUP study, only two original studies used LC&#x02013;MS/MS [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], all others relied on less specific and sensitive immunoassay. Cut-offs for biochemical hyperandrogenism varied, with arbitrary thresholds at the 95th, 97.5th, or 98th percentile of healthy controls. In P-PUP we adapted the 95th percentile cut-off for androgens specific to each study to harmonize data reporting a prevalence from 11.0 to 30.3% in original studies, with an overall prevalence of 20.4%. Further cluster analyses are underway to refine definitions and address persisting limitations.</p><p id="Par78">PCOM is evaluated using pelvic ultrasonography and is characterized by either ovarian enlargement, measured as increased OV, and/or an excess of small antral follicles, either within the entire ovary (FNPO) or a single cross-sectional image (FNPS) [<xref ref-type="bibr" rid="CR68">68</xref>]. Cut-offs for OV and FNPO vary by ultrasound technology and approach. The 2023 International PCOS Guidelines recommend the transvaginal ultrasound approach, FNPO&#x02009;&#x02265;&#x02009;20 in at least one ovary or OV&#x02009;&#x02265;&#x02009;10&#x000a0;ml to define PCOM in adults. If older ultrasound technology is used, the AFC count is&#x02009;&#x02265;&#x02009;12 in at least one ovary. PCOM is not recommended in adolescents as it lacks specificity [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. In the present analysis, only one study adhered to these recommendations and transabdominal and transrectal ultrasound approaches were also used, with no validated PCOM cut-offs, limiting harmonization and resulting in the retention of original study definitions. Guidelines now clearly recommend a transvaginal ultrasound, and cut-offs for FNPO and OV which need to be applied, along with the inclusion of AMH measurements.</p><sec id="Sec17"><title>Strengths and limitations</title><p id="Par79">This study has several strengths. Firstly, this IPD is unique and includes a large diverse, international IPD set, with generalizability to those with PCOS. Unselected participants also minimize selection bias, as seen in clinic-based cohorts. Also, the IPD analysis allowed standardization of definitions and cut-offs across studies and aligned with the 2023 International PCOS Guidelines to minimize heterogeneity and enhance comparability. Limitations include heterogeneity in data collection methods, particularly for ovulatory dysfunction, hyperandrogenism, and PCOM. Some original data could not be harmonized, affecting the comparability of results across populations. Most original studies relied on immunoassays for androgen measurement, which are less accurate than LC-MS/MS. Most studies also used older ultrasound technology and variable approaches and lacked sufficient methodological detail, with reliance on original study PCOM definitions. Although serum AMH is now recommended as an alternative marker for PCOM, this data was not available. Lastly, although the study included participants from four continents and eight countries, including participants from diverse ethnic backgrounds enhanced generalizability, notable geographic and cultural gaps in representation persist, underscoring the need for more globally comprehensive PCOS research.</p></sec></sec><sec id="Sec18"><title>Conclusions</title><p id="Par80">The P-PUP study brings together an unprecedented cohort of ethnically diverse, unselected population-level data to enable research and advance knowledge in PCOS. In integrating this IPD we have shown a lack of standardized data collection methods across original studies. Cut-offs for PCOS diagnostic features also vary, jeopardizing diagnostic accuracy and consistency and impacting data harmonization. This work directly addresses the high research priorities identified in the PCOS Guidelines research roadmap, which emphasizes creating international data repositories and standardizing research approaches [<xref ref-type="bibr" rid="CR59">59</xref>]. Future research efforts should prioritize the standardization of data collection methods that align with the International PCOS Guidelines and PCOS core outcome sets [<xref ref-type="bibr" rid="CR39">39</xref>], while simultaneously refining definitions and establishing accurate normative cut-offs for individual PCOS diagnostic features. These diagnostic thresholds should be based on cluster analysis and natural groupings, identifying diagnostic clusters that are linked to short and long-term outcomes in medically unbiased, unselected, and diverse populations. This dual approach to standardization would facilitate big data integration and the development of machine learning&#x02013;driven models for precision medicine in PCOS.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4221_MOESM1_ESM.docx"><caption><p>Additional file 1: Table S1. Search strategy for OVID Medline. Table S2. Studies excluded following full-text review. Table S3. Risk of bias assessment using AXIS tool. Table S4. Harmonized variables with definitions in the P-PUP study dataset. Table S5. Data collection methods for ovulatory dysfunction across studies.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A4</term><def><p id="Par21">Androstenedione</p></def></def-item><def-item><term>AFC</term><def><p id="Par22">Antral follicular count</p></def></def-item><def-item><term>BMI</term><def><p id="Par23">Body mass index</p></def></def-item><def-item><term>cFT</term><def><p id="Par24">Calculated free testosterone</p></def></def-item><def-item><term>DBP</term><def><p id="Par25">Diastolic blood pressure</p></def></def-item><def-item><term>DHEAS</term><def><p id="Par26">Dehydroepiandrosterone sulfate</p></def></def-item><def-item><term>FAI</term><def><p id="Par27">Free androgen index</p></def></def-item><def-item><term>FBS</term><def><p id="Par28">Fasting blood sugar</p></def></def-item><def-item><term>FT</term><def><p id="Par29">Free testosterone</p></def></def-item><def-item><term>HDL</term><def><p id="Par30">High-density lipoprotein</p></def></def-item><def-item><term>HOMA-IR</term><def><p id="Par31">Homeostatic model assessment for insulin resistance</p></def></def-item><def-item><term>IPD</term><def><p id="Par32">Individual participant data</p></def></def-item><def-item><term>LDL</term><def><p id="Par33">Low-density lipoprotein</p></def></def-item><def-item><term>mFG</term><def><p id="Par34">Modified Ferriman-Gallwey score</p></def></def-item><def-item><term>NIH</term><def><p id="Par35">National Institute of Health</p></def></def-item><def-item><term>OV</term><def><p id="Par36">Ovarian volume</p></def></def-item><def-item><term>PCOM</term><def><p id="Par37">Polycystic ovary morphology</p></def></def-item><def-item><term>PCOS</term><def><p id="Par38">Polycystic ovary syndrome</p></def></def-item><def-item><term>P-PUP</term><def><p id="Par39">PCOS Phenotype in Unselected Populations</p></def></def-item><def-item><term>SBP</term><def><p id="Par40">Systolic blood pressure</p></def></def-item><def-item><term>TT</term><def><p id="Par41">Total testosterone</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Anju E. Joham and Chau Thien Tay are equal contributors and have joint last authorship.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>We acknowledge all collaborators participating in this individual participant data meta-analysis project for their generous provision of data and scientific expertise. We are profoundly grateful to the many thousands of participants in the individual studies whose contributions made this research possible.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions
</title><p>Author contributions ADB: involved in study design, data analysis, interpretation of results, and manuscript preparation. CTT: study design, supervision of data analysis, interpretation of results, and manuscript preparation. AEJ: involved in funding, supervision, conception, study design, acquisition of data, supervision of data analysis, interpretation of results, and manuscript preparation. A.E: involved in the supervision of data analysis, interpretation of results, and manuscript preparation. HJT: involved in funding, supervision, conception, study design, interpretation of results, and manuscript writing. SK and RA: involved in conception, study design, interpretation of results, and manuscript writing. MBK, RRD, LVS, XZ, AG, FRT, BOY, JJK, LX, and CCM: were involved in original study design, acquisition of data, interpretation of results and manuscript writing. All the authors have read and approved the final version of the manuscript. The corresponding author attests that all listed authors meet the authorship criteria.</p><sec id="FPar1"><title>Authors&#x02019; Twitter handles</title><p id="Par81">Twitter handles: @BahriMahnaz (Mahnaz Bahri Khomami).</p></sec></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by the Australian National Health and Medical Research Council (NHMRC) via the Centre for Research Excellence for Women Health in Reproductive Life (CRE-WHiRL) #1171592. ADB is supported by a PhD scholarship funded by the Monash Graduate Scholarship (MGS) and the Monash International Tuition Scholarship (MITS). CMM received grants from the University of Lagos, Central Research Grant CRC/03/2018, Ferring Pharmaceuticals Grant #2021/2944, and the Foundation for Research and Education Excellence. HJT is supported by NHMRC fellowships #2009326, AEJ is funded by the NHMRC CRE-WhiRL fellowship, CTT is supported by CRE-WHiRL funded by the NHMRC, and RA is supported by funding from the Foundation for Research and Education Excellence.</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>The individual participant data supporting the findings of this study are available at [<ext-link ext-link-type="uri" xlink:href="https://bridges.monash.edu/articles/dataset/The_PCOS_Phenotype_in_Unselected_Populations_Study_P-PUP_/22590316">https://bridges.monash.edu/articles/dataset/The_PCOS_Phenotype_in_Unselected_Populations_Study_P-PUP_/22590316</ext-link>], but restrictions apply. Access requests can be submitted to Anju E Joham (anju.joham@monash.edu) and Chau Thien Tay (jillian.tay@monash.edu), subject to data use agreements and ethical approvals from the respective institutional review boards of the contributing studies.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par82">Ethical approval for the P-PUP study was obtained from the Monash University Human Research Ethics Committee (HUMREC) (ID: 26938). Additionally, each study within the research project received ethical approval from the relevant Human Research Ethics Committee.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par83">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par84">AEJ serves as a Board member for Androgen Excess and Polycystic Ovary Syndrome, received honoraria for presentations at educational events at Novo Nordisk, Boehringer and Merck, and is an employee of Monash Health. CTT serves as Chair of CRE-WHiRL ECR Group 2020-2023 and AEPCOS EC-SIG group 2020-2022, as a committee member of the Endocrine Society of Australia&#x02019;s ECR Group. AG serves on the Editorial Board for the European Journal of Endocrinology and on the Advisory Board of the Italian Society of Endocrinology. RA serves as a consultant to May Health, Core Access Surgical Technologies, Spruce Biosciences, and Postera; is an investor in Martin Imaging; received honoraria for speaking from the Davidson-Mestman course, Merck and Stya Paul Oration; and serves on the Editorial Board for the Journal of Clinical Endocrinology and Metabolism, on the Board of Trustees for the Endocrine Society, as a member of the DSMB for grant NCT03625531; ChiCTR180001730 to The First Affiliated of Guangzhou Medical University and grant for the SUPER study to the University of Michigan, and previously served as CEO of the American Society for Reproductive Medicine. All the other authors declare that they have no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Bozdag</surname><given-names>G</given-names></name><name><surname>Mumusoglu</surname><given-names>S</given-names></name><name><surname>Zengin</surname><given-names>D</given-names></name><name><surname>Karabulut</surname><given-names>E</given-names></name><name><surname>Yildiz</surname><given-names>BO</given-names></name></person-group><article-title>The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis</article-title><source>Hum Reprod</source><year>2016</year><volume>31</volume><issue>12</issue><fpage>2841</fpage><lpage>2855</lpage><?supplied-pmid 27664216?><pub-id pub-id-type="pmid">27664216</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841&#x02013;55.<pub-id pub-id-type="pmid">27664216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Laven</surname><given-names>JJE</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Piltonen</surname><given-names>TT</given-names></name><name><surname>Costello</surname><given-names>MF</given-names></name><name><surname>Boivin</surname><given-names>J</given-names></name><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Boyle</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2023</year><volume>108</volume><issue>10</issue><fpage>2447</fpage><lpage>2469</lpage><?supplied-pmid 37580314?><pub-id pub-id-type="pmid">37580314</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447&#x02013;69.<pub-id pub-id-type="pmid">37580314</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Laven</surname><given-names>JJE</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Piltonen</surname><given-names>TT</given-names></name><name><surname>Costello</surname><given-names>MF</given-names></name><name><surname>Boivin</surname><given-names>J</given-names></name><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Boyle</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome</article-title><source>Eur J Endocrinol</source><year>2023</year><volume>189</volume><issue>2</issue><fpage>G43</fpage><lpage>G64</lpage><?supplied-pmid 37580861?><pub-id pub-id-type="pmid">37580861</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43&#x02013;64.<pub-id pub-id-type="pmid">37580861</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Piltonen</surname><given-names>TT</given-names></name><name><surname>Costello</surname><given-names>MF</given-names></name><name><surname>Boivin</surname><given-names>J</given-names></name><name><surname>Redman</surname><given-names>LM</given-names></name><name><surname>Boyle</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome</article-title><source>Hum Reprod</source><year>2023</year><volume>38</volume><issue>9</issue><fpage>1655</fpage><lpage>1679</lpage><?supplied-pmid 37580037?><pub-id pub-id-type="pmid">37580037</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655&#x02013;79.<pub-id pub-id-type="pmid">37580037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>LJ</given-names></name><name><surname>Piltonen</surname><given-names>TT</given-names></name><name><surname>Costello</surname><given-names>MF</given-names></name><name><surname>Boivin</surname><given-names>JM</given-names></name><name><surname>Redman</surname><given-names>LA</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome</article-title><source>Fertil Steril.</source><year>2023</year><volume>120</volume><issue>4</issue><fpage>767</fpage><lpage>793</lpage><?supplied-pmid 37589624?><pub-id pub-id-type="pmid">37589624</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin JM, Redman LA, Boyle J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767&#x02013;93.<pub-id pub-id-type="pmid">37589624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Misso</surname><given-names>ML</given-names></name><name><surname>Costello</surname><given-names>MF</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Moran</surname><given-names>L</given-names></name><name><surname>Piltonen</surname><given-names>T</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name></person-group><article-title>Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome</article-title><source>Hum Reprod</source><year>2018</year><volume>33</volume><issue>9</issue><fpage>1602</fpage><lpage>1618</lpage><?supplied-pmid 30052961?><pub-id pub-id-type="pmid">30052961</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602&#x02013;18.<pub-id pub-id-type="pmid">30052961</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>L</given-names></name></person-group><article-title>Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017</article-title><source>Hum Reprod</source><year>2021</year><volume>36</volume><issue>4</issue><fpage>1108</fpage><lpage>1119</lpage><?supplied-pmid 33501984?><pub-id pub-id-type="pmid">33501984</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, Han L. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021;36(4):1108&#x02013;19.<pub-id pub-id-type="pmid">33501984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Safiri</surname><given-names>S</given-names></name><name><surname>Noori</surname><given-names>M</given-names></name><name><surname>Nejadghaderi</surname><given-names>SA</given-names></name><name><surname>Karamzad</surname><given-names>N</given-names></name><name><surname>Carson-Chahhoud</surname><given-names>K</given-names></name><name><surname>Sullman</surname><given-names>MJ</given-names></name><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Kolahi</surname><given-names>A-A</given-names></name><name><surname>Avery</surname><given-names>J</given-names></name></person-group><article-title>Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990&#x02013;2019</article-title><source>Hum Reprod</source><year>2022</year><volume>37</volume><issue>8</issue><fpage>1919</fpage><lpage>1931</lpage><?supplied-pmid 35586937?><pub-id pub-id-type="pmid">35586937</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Safiri S, Noori M, Nejadghaderi SA, Karamzad N, Carson-Chahhoud K, Sullman MJ, Collins GS, Kolahi A-A, Avery J. Prevalence, incidence and years lived with disability due to polycystic ovary syndrome in 204 countries and territories, 1990&#x02013;2019. Hum Reprod. 2022;37(8):1919&#x02013;31.<pub-id pub-id-type="pmid">35586937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Marin</surname><given-names>C</given-names></name><name><surname>Hoq</surname><given-names>L</given-names></name><name><surname>Badamgarav</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>P</given-names></name></person-group><article-title>Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><issue>8</issue><fpage>4650</fpage><lpage>4658</lpage><?supplied-pmid 15944216?><pub-id pub-id-type="pmid">15944216</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90(8):4650&#x02013;8.<pub-id pub-id-type="pmid">15944216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Riestenberg</surname><given-names>C</given-names></name><name><surname>Jagasia</surname><given-names>A</given-names></name><name><surname>Markovic</surname><given-names>D</given-names></name><name><surname>Buyalos</surname><given-names>RP</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Health care-related economic burden of polycystic ovary syndrome in the United States: pregnancy-related and long-term health consequences</article-title><source>J Clin Endocrinol Metab</source><year>2022</year><volume>107</volume><issue>2</issue><fpage>575</fpage><lpage>585</lpage><?supplied-pmid 34546364?><pub-id pub-id-type="pmid">34546364</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health care-related economic burden of polycystic ovary syndrome in the United States: pregnancy-related and long-term health consequences. J Clin Endocrinol Metab. 2022;107(2):575&#x02013;85.<pub-id pub-id-type="pmid">34546364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Yadav S, Delau O, Bonner AJ, Markovic D, Patterson W, Ottey S, Buyalos RP, Azziz R. Direct economic burden of mental health disorders associated with polycystic ovary syndrome: Systematic review and meta-analysis. Elife. 2023;12:e85338.</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Deeks</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>L</given-names></name></person-group><article-title>Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan</article-title><source>BMC Med</source><year>2010</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">20051100</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1):1&#x02013;10.<pub-id pub-id-type="pmid">20051100</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name></person-group><article-title>Past and present: a bibliometric study on polycystic ovary syndrome</article-title><source>J Ovarian Res</source><year>2023</year><volume>16</volume><issue>1</issue><fpage>42</fpage><lpage>42</lpage><?supplied-pmid 36803912?><pub-id pub-id-type="pmid">36803912</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Cai M, Ni Z, Yuan Z, Yu J, Zhang D, Yao R, Zhou L, Yu C. Past and present: a bibliometric study on polycystic ovary syndrome. J Ovarian Res. 2023;16(1):42&#x02013;42.<pub-id pub-id-type="pmid">36803912</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Engmann</surname><given-names>LMD</given-names></name><name><surname>Jin</surname><given-names>SMPH</given-names></name><name><surname>Sun</surname><given-names>FMPH</given-names></name><name><surname>Legro</surname><given-names>RSMD</given-names></name><name><surname>Polotsky</surname><given-names>AJMDM</given-names></name><name><surname>Hansen</surname><given-names>KRMDP</given-names></name><name><surname>Coutifaris</surname><given-names>CMDP</given-names></name><name><surname>Diamond</surname><given-names>MPMD</given-names></name><name><surname>Eisenberg</surname><given-names>EMDMPH</given-names></name><name><surname>Zhang</surname><given-names>HP</given-names></name><etal/></person-group><article-title>Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype</article-title><source>Am J Obstet Gynecol.</source><year>2017</year><volume>216</volume><issue>5</issue><fpage>493</fpage></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Engmann LMD, Jin SMPH, Sun FMPH, Legro RSMD, Polotsky AJMDM, Hansen KRMDP, Coutifaris CMDP, Diamond MPMD, Eisenberg EMDMPH, Zhang HP, et al. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. Am J Obstet Gynecol. 2017;216(5):493 e491-493.e413.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>VanHise</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>ET</given-names></name><name><surname>Norris</surname><given-names>K</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Pisarska</surname><given-names>MD</given-names></name><name><surname>Chan</surname><given-names>JL</given-names></name></person-group><article-title>Racial and ethnic disparities in polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2023</year><volume>119</volume><issue>3</issue><fpage>348</fpage><lpage>354</lpage><?supplied-pmid 36702345?><pub-id pub-id-type="pmid">36702345</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">VanHise K, Wang ET, Norris K, Azziz R, Pisarska MD, Chan JL. Racial and ethnic disparities in polycystic ovary syndrome. Fertil Steril. 2023;119(3):348&#x02013;54.<pub-id pub-id-type="pmid">36702345</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Kintziger</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Morin-Papunen</surname><given-names>L</given-names></name><name><surname>Merkin</surname><given-names>SS</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Yildiz</surname><given-names>BO</given-names></name></person-group><article-title>Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource</article-title><source>Hum Reprod</source><year>2019</year><volume>34</volume><issue>11</issue><fpage>2254</fpage><lpage>2265</lpage><?supplied-pmid 31751476?><pub-id pub-id-type="pmid">31751476</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Azziz R, Kintziger K, Li R, Laven J, Morin-Papunen L, Merkin SS, Teede H, Yildiz BO. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. Hum Reprod. 2019;34(11):2254&#x02013;65.<pub-id pub-id-type="pmid">31751476</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Luque-Ram&#x000ed;rez</surname><given-names>M</given-names></name><name><surname>Alpa&#x000f1;&#x000e9;s</surname><given-names>M</given-names></name><name><surname>Sanch&#x000f3;n</surname><given-names>R</given-names></name><name><surname>Fern&#x000e1;ndez-Dur&#x000e1;n</surname><given-names>E</given-names></name><name><surname>Ortiz-Flores</surname><given-names>AE</given-names></name><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name></person-group><article-title>Referral bias in female functional hyperandrogenism and polycystic ovary syndrome</article-title><source>Eur J Endocrinol</source><year>2015</year><volume>173</volume><issue>5</issue><fpage>603</fpage><lpage>610</lpage><?supplied-pmid 26243032?><pub-id pub-id-type="pmid">26243032</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Luque-Ram&#x000ed;rez M, Alpa&#x000f1;&#x000e9;s M, Sanch&#x000f3;n R, Fern&#x000e1;ndez-Dur&#x000e1;n E, Ortiz-Flores AE, Escobar-Morreale HF. Referral bias in female functional hyperandrogenism and polycystic ovary syndrome. Eur J Endocrinol. 2015;173(5):603&#x02013;10.<pub-id pub-id-type="pmid">26243032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Kirubakaran</surname><given-names>R</given-names></name><name><surname>Mykhalchenko</surname><given-names>K</given-names></name><name><surname>Suturina</surname><given-names>L</given-names></name><name><surname>Chernukha</surname><given-names>G</given-names></name><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis</article-title><source>Fertil Steril.</source><year>2016</year><volume>106</volume><issue>6</issue><fpage>1510</fpage><lpage>1520</lpage><?supplied-pmid 27530062?><pub-id pub-id-type="pmid">27530062</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;106(6):1510&#x02013;20 e1512.<pub-id pub-id-type="pmid">27530062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ezeh</surname><given-names>U</given-names></name><name><surname>Yildiz</surname><given-names>BO</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>6</issue><fpage>E1088</fpage><lpage>E1096</lpage><?supplied-pmid 23539721?><pub-id pub-id-type="pmid">23539721</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):E1088&#x02013;96.<pub-id pub-id-type="pmid">23539721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992:377&#x02013;384.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><collab>Rotterdam ESHRE ASRM Sponsored PCOS Consensus Workshop Group</collab></person-group><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">14688154</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Rotterdam ESHRE ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41&#x02013;7.<pub-id pub-id-type="pmid">14688154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Dewailly</surname><given-names>D</given-names></name><name><surname>Diamanti-Kandarakis</surname><given-names>E</given-names></name><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name><name><surname>Futterweit</surname><given-names>W</given-names></name><name><surname>Janssen</surname><given-names>OE</given-names></name><name><surname>Legro</surname><given-names>RS</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name></person-group><article-title>Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><issue>11</issue><fpage>4237</fpage><lpage>4245</lpage><?supplied-pmid 16940456?><pub-id pub-id-type="pmid">16940456</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237&#x02013;45.<pub-id pub-id-type="pmid">16940456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><collab>Group REASPCW</collab></person-group><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)</article-title><source>Hum Reprod.</source><year>2004</year><volume>19</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">14688154</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Group REASPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41&#x02013;7.<pub-id pub-id-type="pmid">14688154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Taieb</surname><given-names>J</given-names></name><name><surname>Mathian</surname><given-names>B</given-names></name><name><surname>Millot</surname><given-names>F</given-names></name><name><surname>Patricot</surname><given-names>MC</given-names></name><name><surname>Mathieu</surname><given-names>E</given-names></name><name><surname>Queyrel</surname><given-names>N</given-names></name><name><surname>Lacroix</surname><given-names>I</given-names></name><name><surname>Somma-Delpero</surname><given-names>C</given-names></name><name><surname>Boudou</surname><given-names>P</given-names></name></person-group><article-title>Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><issue>8</issue><fpage>1381</fpage><lpage>1395</lpage><?supplied-pmid 12881456?><pub-id pub-id-type="pmid">12881456</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49(8):1381&#x02013;95.<pub-id pub-id-type="pmid">12881456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>DeUgarte</surname><given-names>CM</given-names></name><name><surname>Woods</surname><given-names>K</given-names></name><name><surname>Bartolucci</surname><given-names>AA</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><issue>4</issue><fpage>1345</fpage><lpage>1350</lpage><?supplied-pmid 16449347?><pub-id pub-id-type="pmid">16449347</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">DeUgarte CM, Woods K, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91(4):1345&#x02013;50.<pub-id pub-id-type="pmid">16449347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JJ</given-names></name><name><surname>Chae</surname><given-names>SJ</given-names></name><name><surname>Choi</surname><given-names>YM</given-names></name><name><surname>Hwang</surname><given-names>SS</given-names></name><name><surname>Hwang</surname><given-names>KR</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>SY</given-names></name></person-group><article-title>Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up</article-title><source>Hum Reprod</source><year>2011</year><volume>26</volume><issue>1</issue><fpage>214</fpage><lpage>220</lpage><?supplied-pmid 21098626?><pub-id pub-id-type="pmid">21098626</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, Yoon SH, Moon SY. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod. 2011;26(1):214&#x02013;20.<pub-id pub-id-type="pmid">21098626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name></person-group><article-title>Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2012</year><volume>163</volume><issue>2</issue><fpage>165</fpage><lpage>169</lpage><?supplied-pmid 22748844?><pub-id pub-id-type="pmid">22748844</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Li R, Qiao J, Yang D, Li S, Lu S, Wu X, Wei Z. Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):165&#x02013;9.<pub-id pub-id-type="pmid">22748844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000d6;Ner</surname><given-names>N</given-names></name><name><surname>Ekmek&#x000c7;&#x00130;</surname><given-names>TR</given-names></name></person-group><article-title>Criticising Modified Ferriman-Gallwey Scroring System in the Evaluation of Hirsutism in 1034 Turkish Women</article-title><source>Turkiye Klinikleri J Med Sci</source><year>2013</year><volume>33</volume><issue>2</issue><fpage>314</fpage><lpage>320</lpage></element-citation><mixed-citation id="mc-CR28" publication-type="journal">D&#x000d6;Ner N, Ekmek&#x000c7;&#x00130; TR. Criticising Modified Ferriman-Gallwey Scroring System in the Evaluation of Hirsutism in 1034 Turkish Women. Turkiye Klinikleri J Med Sci. 2013;33(2):314&#x02013;20.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name></person-group><article-title>Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years</article-title><source>Reprod Biomed Online</source><year>2017</year><volume>35</volume><issue>3</issue><fpage>331</fpage><lpage>339</lpage><?supplied-pmid 28684272?><pub-id pub-id-type="pmid">28684272</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhou Z, Li R, Qiao J. Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years. Reprod Biomed Online. 2017;35(3):331&#x02013;9.<pub-id pub-id-type="pmid">28684272</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilagan</surname><given-names>MKCC</given-names></name><name><surname>Paz-Pacheco</surname><given-names>E</given-names></name><name><surname>Totesora</surname><given-names>DZ</given-names></name><name><surname>Clemente-Chua</surname><given-names>LR</given-names></name><name><surname>Jalique</surname><given-names>JRK</given-names></name></person-group><article-title>The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women</article-title><source>Endocrinol Metab</source><year>2019</year><volume>34</volume><issue>4</issue><fpage>374</fpage><lpage>381</lpage></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ilagan MKCC, Paz-Pacheco E, Totesora DZ, Clemente-Chua LR, Jalique JRK. The Modified Ferriman-Gallwey Score and Hirsutism among Filipino Women. Endocrinol Metab. 2019;34(4):374&#x02013;81.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Suturina</surname><given-names>L</given-names></name><name><surname>Lizneva</surname><given-names>D</given-names></name><name><surname>Atalyan</surname><given-names>A</given-names></name><name><surname>Lazareva</surname><given-names>L</given-names></name><name><surname>Belskikh</surname><given-names>A</given-names></name><name><surname>Bairova</surname><given-names>T</given-names></name><name><surname>Sholokhov</surname><given-names>L</given-names></name><name><surname>Rashidova</surname><given-names>M</given-names></name><name><surname>Danusevich</surname><given-names>I</given-names></name><name><surname>Nadeliaeva</surname><given-names>I</given-names></name><etal/></person-group><article-title>Establishing Normative Values to Determine the Prevalence of Biochemical Hyperandrogenism in Premenopausal Women of Different Ethnicities from Eastern Siberia</article-title><source>Diagnostics (Basel)</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>33</fpage><?supplied-pmid 36611327?><pub-id pub-id-type="pmid">36611327</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Suturina L, Lizneva D, Atalyan A, Lazareva L, Belskikh A, Bairova T, Sholokhov L, Rashidova M, Danusevich I, Nadeliaeva I, et al. Establishing Normative Values to Determine the Prevalence of Biochemical Hyperandrogenism in Premenopausal Women of Different Ethnicities from Eastern Siberia. Diagnostics (Basel). 2022;13(1):33.<pub-id pub-id-type="pmid">36611327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson-Helm</surname><given-names>M</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Dunaif</surname><given-names>A</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name></person-group><article-title>Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2017</year><volume>102</volume><issue>2</issue><fpage>604</fpage><lpage>612</lpage><?supplied-pmid 27906550?><pub-id pub-id-type="pmid">27906550</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(2):604&#x02013;12.<pub-id pub-id-type="pmid">27906550</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcock</surname><given-names>J</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name></person-group><article-title>Polycystic ovarian syndrome: overdiagnosed and overtreated?</article-title><source>Br J Gen Pract</source><year>2018</year><volume>68</volume><issue>670</issue><fpage>243</fpage><lpage>243</lpage><?supplied-pmid 29700036?><pub-id pub-id-type="pmid">29700036</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wilcock J, Taylor D. Polycystic ovarian syndrome: overdiagnosed and overtreated? Br J Gen Pract. 2018;68(670):243&#x02013;243.<pub-id pub-id-type="pmid">29700036</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Joham</surname><given-names>AE</given-names></name><name><surname>Piltonen</surname><given-names>T</given-names></name><name><surname>Lujan</surname><given-names>ME</given-names></name><name><surname>Kiconco</surname><given-names>S</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name></person-group><article-title>Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome</article-title><source>Clin Endocrinol (Oxf)</source><year>2022</year><volume>97</volume><issue>2</issue><fpage>165</fpage><lpage>173</lpage><?supplied-pmid 35593530?><pub-id pub-id-type="pmid">35593530</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Joham AE, Piltonen T, Lujan ME, Kiconco S, Tay CT. Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2022;97(2):165&#x02013;73.<pub-id pub-id-type="pmid">35593530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Saini</surname><given-names>S</given-names></name><name><surname>Gibson-Helm</surname><given-names>M</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Cooney</surname><given-names>L</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name></person-group><article-title>Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome</article-title><source>Fertil Steril.</source><year>2017</year><volume>107</volume><issue>6</issue><fpage>1380</fpage><lpage>1386</lpage><?supplied-pmid 28483503?><pub-id pub-id-type="pmid">28483503</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107(6):1380&#x02013;6 e1381.<pub-id pub-id-type="pmid">28483503</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Kiconco S, Mousa A, Azziz R, Enticott J, Suturina LV, Zhao X, Gambineri A, Tehrani FR, Yildiz BO, Kim JJ, et al. PCOS Phenotype in Unselected Populations Study (P-PUP): Protocol for a Systematic Review and Defining PCOS Diagnostic Features with Pooled Individual Participant Data. Diagnostics (Basel). 2021;11(11):1953.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Clarke</surname><given-names>M</given-names></name><name><surname>Rovers</surname><given-names>M</given-names></name><name><surname>Riley</surname><given-names>RD</given-names></name><name><surname>Simmonds</surname><given-names>M</given-names></name><name><surname>Stewart</surname><given-names>G</given-names></name><name><surname>Tierney</surname><given-names>JF</given-names></name></person-group><article-title>Group ftP-ID: Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement</article-title><source>JAMA</source><year>2015</year><volume>313</volume><issue>16</issue><fpage>1657</fpage><lpage>1665</lpage><?supplied-pmid 25919529?><pub-id pub-id-type="pmid">25919529</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Group ftP-ID: Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement. JAMA. 2015;313(16):1657&#x02013;65.<pub-id pub-id-type="pmid">25919529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>KH</given-names></name><name><surname>Ford</surname><given-names>DV</given-names></name><name><surname>Ellwood-Thompson</surname><given-names>S</given-names></name><name><surname>Lyons</surname><given-names>RA</given-names></name></person-group><article-title>The UK Secure eResearch Platform for public health research: a case study</article-title><source>The Lancet</source><year>2016</year><volume>388</volume><fpage>S62</fpage></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Jones KH, Ford DV, Ellwood-Thompson S, Lyons RA. The UK Secure eResearch Platform for public health research: a case study. The Lancet. 2016;388:S62.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Al Wattar</surname><given-names>BH</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Garad</surname><given-names>R</given-names></name><name><surname>Franks</surname><given-names>S</given-names></name><name><surname>Balen</surname><given-names>A</given-names></name><name><surname>Bhide</surname><given-names>P</given-names></name><name><surname>Piltonen</surname><given-names>T</given-names></name><name><surname>Romualdi</surname><given-names>D</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Thondan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set</article-title><source>Hum Reprod</source><year>2020</year><volume>35</volume><issue>2</issue><fpage>404</fpage><lpage>412</lpage><?supplied-pmid 32020203?><pub-id pub-id-type="pmid">32020203</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Al Wattar BH, Teede H, Garad R, Franks S, Balen A, Bhide P, Piltonen T, Romualdi D, Laven J, Thondan M, et al. Harmonising research outcomes for polycystic ovary syndrome: an international multi-stakeholder core outcome set. Hum Reprod. 2020;35(2):404&#x02013;12.<pub-id pub-id-type="pmid">32020203</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Downes</surname><given-names>MJ</given-names></name><name><surname>Brennan</surname><given-names>ML</given-names></name><name><surname>Williams</surname><given-names>HC</given-names></name><name><surname>Dean</surname><given-names>RS</given-names></name></person-group><article-title>Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS)</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><issue>12</issue><fpage>e011458</fpage><?supplied-pmid 27932337?><pub-id pub-id-type="pmid">27932337</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12): e011458.<pub-id pub-id-type="pmid">27932337</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Oliver E, Coates A, Bennett JM, Willis ML. Narcissism and Intimate Partner Violence: A Systematic Review and Meta-Analysis. Trauma Violence Abuse. 2024;25(3):1871&#x02013;84.</mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>V</given-names></name></person-group><article-title>Outliers in statistical data</article-title><source>Wiley&#x00026;nbsp;</source><year>1994</year><volume>2</volume><fpage>705</fpage><lpage>708</lpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Barnett V, Lewis T. Outliers in statistical data. 3rd ed. Chichester: Wiley;1994.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Bizuneh</surname><given-names>AD</given-names></name><name><surname>Joham</surname><given-names>AE</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Kiconco</surname><given-names>S</given-names></name><name><surname>Earnest</surname><given-names>A</given-names></name><name><surname>Dhungana</surname><given-names>RR</given-names></name><name><surname>Suturina</surname><given-names>LV</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Gambineri</surname><given-names>A</given-names></name><name><surname>Ramezani Tehrani</surname><given-names>F</given-names></name><etal/></person-group><article-title>The PCOS Phenotype in Unselected Populations study: ethnic variation in population-based normative cut-offs for defining hirsutism</article-title><source>Eur J Endocrinol</source><year>2025</year><volume>192</volume><issue>3</issue><fpage>228</fpage><lpage>239</lpage><?supplied-pmid 40036973?><pub-id pub-id-type="pmid">40036973</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Bizuneh AD, Joham AE, Tay CT, Kiconco S, Earnest A, Dhungana RR, Suturina LV, Zhao X, Gambineri A, Ramezani Tehrani F, et al. The PCOS Phenotype in Unselected Populations study: ethnic variation in population-based normative cut-offs for defining hirsutism. Eur J Endocrinol. 2025;192(3):228&#x02013;39.<pub-id pub-id-type="pmid">40036973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Prevalence of polycystic ovary syndrome in unselected women from southern China</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2008</year><volume>139</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><?supplied-pmid 18378061?><pub-id pub-id-type="pmid">18378061</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008;139(1):59&#x02013;64.<pub-id pub-id-type="pmid">18378061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>B</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Patil</surname><given-names>A</given-names></name><name><surname>Purandare</surname><given-names>A</given-names></name><name><surname>Chauhan</surname><given-names>S</given-names></name><name><surname>Vaidya</surname><given-names>R</given-names></name></person-group><article-title>A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai</article-title><source>India Indian J Endocrinol Metab</source><year>2014</year><volume>18</volume><issue>3</issue><fpage>317</fpage><lpage>324</lpage><?supplied-pmid 24944925?><pub-id pub-id-type="pmid">24944925</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai. India Indian J Endocrinol Metab. 2014;18(3):317&#x02013;24.<pub-id pub-id-type="pmid">24944925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence of polycystic ovary syndrome in women in China: a large community-based study</article-title><source>Hum Reprod</source><year>2013</year><volume>28</volume><issue>9</issue><fpage>2562</fpage><lpage>2569</lpage><?supplied-pmid 23814096?><pub-id pub-id-type="pmid">23814096</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28(9):2562&#x02013;9.<pub-id pub-id-type="pmid">23814096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Makwe CC, Olamijulo JA, Balogun MR, Akinkugbe AO, Samuel A, Udenze K, Bril F, Buyalos RP, Laven JSE, Azziz R. SAT363 The Prevalence And Phenotype Of Polycystic Ovary Syndrome (PCOS) In A Community-Based Population In Sub-Sahara Africa: The Nigeria-PEP Study. J Endocr Soc. 2023;7(Supplement_1).</mixed-citation></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prevalence of the Polycystic Ovary Syndrome in Female Residents of Chengdu</article-title><source>China Gynecol Obstet Invest</source><year>2014</year><volume>77</volume><issue>4</issue><fpage>217</fpage><lpage>223</lpage><?supplied-pmid 24751759?><pub-id pub-id-type="pmid">24751759</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Zhuang J, Liu Y, Xu L, Liu X, Zhou L, Tang L, Kang D, Guo W, He M, Yang F, et al. Prevalence of the Polycystic Ovary Syndrome in Female Residents of Chengdu. China Gynecol Obstet Invest. 2014;77(4):217&#x02013;223.<pub-id pub-id-type="pmid">24751759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Tehrani</surname><given-names>FR</given-names></name><name><surname>Rashidi</surname><given-names>H</given-names></name><name><surname>Khomami</surname><given-names>MB</given-names></name><name><surname>Tohidi</surname><given-names>M</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran</article-title><source>Reprod Biol Endocrinol</source><year>2014</year><volume>12</volume><issue>1</issue><fpage>89</fpage><lpage>89</lpage><?supplied-pmid 25224635?><pub-id pub-id-type="pmid">25224635</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014;12(1):89&#x02013;89.<pub-id pub-id-type="pmid">25224635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Gambineri</surname><given-names>A</given-names></name><name><surname>Fanelli</surname><given-names>F</given-names></name><name><surname>Prontera</surname><given-names>O</given-names></name><name><surname>Repaci</surname><given-names>A</given-names></name><name><surname>Di Dalmazi</surname><given-names>G</given-names></name><name><surname>Zanotti</surname><given-names>L</given-names></name><name><surname>Pagotto</surname><given-names>U</given-names></name><name><surname>Flacco</surname><given-names>ME</given-names></name><name><surname>Guidi</surname><given-names>J</given-names></name><name><surname>Fava</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>4</issue><fpage>1641</fpage><lpage>1650</lpage><?supplied-pmid 23436925?><pub-id pub-id-type="pmid">23436925</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Gambineri A, Fanelli F, Prontera O, Repaci A, Di Dalmazi G, Zanotti L, Pagotto U, Flacco ME, Guidi J, Fava GA, et al. Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students. J Clin Endocrinol Metab. 2013;98(4):1641&#x02013;50.<pub-id pub-id-type="pmid">23436925</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>BO</given-names></name><name><surname>Bozdag</surname><given-names>G</given-names></name><name><surname>Yapici</surname><given-names>Z</given-names></name><name><surname>Esinler</surname><given-names>I</given-names></name><name><surname>Yarali</surname><given-names>H</given-names></name></person-group><article-title>Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria</article-title><source>Hum Reprod</source><year>2012</year><volume>27</volume><issue>10</issue><fpage>3067</fpage><lpage>3073</lpage><?supplied-pmid 22777527?><pub-id pub-id-type="pmid">22777527</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067&#x02013;73.<pub-id pub-id-type="pmid">22777527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>XMDPD</given-names></name><name><surname>Ni</surname><given-names>RMDPD</given-names></name><name><surname>Li</surname><given-names>LLMDPD</given-names></name><name><surname>Mo</surname><given-names>YPD</given-names></name><name><surname>Huang</surname><given-names>JMD</given-names></name><name><surname>Huang</surname><given-names>MMD</given-names></name><name><surname>Azziz</surname><given-names>RMDMBAMPH</given-names></name><name><surname>Yang</surname><given-names>DMDPD</given-names></name></person-group><article-title>Defining hirsutism in Chinese women: a cross-sectional study</article-title><source>Fertil Steril.</source><year>2011</year><volume>96</volume><issue>3</issue><fpage>792</fpage><lpage>796</lpage><?supplied-pmid 21762890?><pub-id pub-id-type="pmid">21762890</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Zhao XMDPD, Ni RMDPD, Li LLMDPD, Mo YPD, Huang JMD, Huang MMD, Azziz RMDMBAMPH, Yang DMDPD. Defining hirsutism in Chinese women: a cross-sectional study. Fertil Steril. 2011;96(3):792&#x02013;6.<pub-id pub-id-type="pmid">21762890</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Tehrani</surname><given-names>FR</given-names></name><name><surname>Simbar</surname><given-names>M</given-names></name><name><surname>Tohidi</surname><given-names>M</given-names></name><name><surname>Hosseinpanah</surname><given-names>F</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study</article-title><source>Reprod Biol Endocrinol</source><year>2011</year><volume>9</volume><issue>1</issue><fpage>39</fpage><lpage>39</lpage><?supplied-pmid 21435276?><pub-id pub-id-type="pmid">21435276</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol. 2011;9(1):39&#x02013;39.<pub-id pub-id-type="pmid">21435276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Tehrani</surname><given-names>FR</given-names></name><name><surname>Rashidi</surname><given-names>H</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study</article-title><source>Reprod Biol Endocrinol</source><year>2011</year><volume>9</volume><issue>1</issue><fpage>144</fpage><lpage>144</lpage><?supplied-pmid 22044512?><pub-id pub-id-type="pmid">22044512</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Tehrani FR, Rashidi H, Azizi F. The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study. Reprod Biol Endocrinol. 2011;9(1):144&#x02013;144.<pub-id pub-id-type="pmid">22044512</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Woods</surname><given-names>KS</given-names></name><name><surname>Reyna</surname><given-names>R</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Knochenhauer</surname><given-names>ES</given-names></name><name><surname>Yildiz</surname><given-names>BO</given-names></name></person-group><article-title>The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><issue>6</issue><fpage>2745</fpage><lpage>2749</lpage><?supplied-pmid 15181052?><pub-id pub-id-type="pmid">15181052</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. J Clin Endocrinol Metab. 2004;89(6):2745&#x02013;9.<pub-id pub-id-type="pmid">15181052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Knochenhauer</surname><given-names>ES</given-names></name><name><surname>Key</surname><given-names>TJ</given-names></name><name><surname>Kahsar-Miller</surname><given-names>M</given-names></name><name><surname>Waggoner</surname><given-names>W</given-names></name><name><surname>Boots</surname><given-names>LR</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Prevalence of the polycystic ovary syndrome in unselected Black and White women of the Southeastern United States : A prospective study</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><issue>9</issue><fpage>3078</fpage><lpage>3082</lpage><?supplied-pmid 9745406?><pub-id pub-id-type="pmid">9745406</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the Southeastern United States&#x0202f;: A prospective study. J Clin Endocrinol Metab. 1998;83(9):3078&#x02013;82.<pub-id pub-id-type="pmid">9745406</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Treloar</surname><given-names>AE</given-names></name><name><surname>Boynton</surname><given-names>RE</given-names></name><name><surname>Behn</surname><given-names>BG</given-names></name><name><surname>Brown</surname><given-names>BW</given-names></name></person-group><article-title>The menstrual cycle: Variation of the human menstrual cycle through reproductive life</article-title><source>Obstet Gynecol Surv</source><year>1968</year><volume>23</volume><issue>1</issue><fpage>81</fpage><lpage>84</lpage></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Treloar AE, Boynton RE, Behn BG, Brown BW. The menstrual cycle: Variation of the human menstrual cycle through reproductive life. Obstet Gynecol Surv. 1968;23(1):81&#x02013;4.</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Response to Letter to the Editor From Rosenfield et al:&#x0201c;Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome&#x0201d;</article-title><source>J Clin Endocrinol Metab.</source><year>2024</year><volume>109</volume><issue>10</issue><fpage>e1976</fpage><lpage>e1977</lpage><?supplied-pmid 38809769?><pub-id pub-id-type="pmid">38809769</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Teede H, Tay CT, Azziz R. Response to Letter to the Editor From Rosenfield et al:&#x0201c;Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.&#x0201d; J Clin Endocrinol Metab. 2024;109(10):e1976&#x02013;7.<pub-id pub-id-type="pmid">38809769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Gibson</surname><given-names>M</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Dokras</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>L</given-names></name><name><surname>Piltonin</surname><given-names>T</given-names></name><name><surname>Costello</surname><given-names>M</given-names></name><name><surname>Mousa</surname><given-names>A</given-names></name><name><surname>Joham</surname><given-names>A</given-names></name><name><surname>Tay</surname><given-names>C</given-names></name></person-group><article-title>International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women&#x02019;s health condition</article-title><source>EClinicalMedicine</source><year>2024</year><volume>78</volume><fpage>102927</fpage><lpage>102927</lpage><?supplied-pmid 39634033?><pub-id pub-id-type="pmid">39634033</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Teede H, Gibson M, Laven J, Dokras A, Moran L, Piltonin T, Costello M, Mousa A, Joham A, Tay C. International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women&#x02019;s health condition. EClinicalMedicine. 2024;78:102927&#x02013;102927.<pub-id pub-id-type="pmid">39634033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Sanchez</surname><given-names>LA</given-names></name><name><surname>Knochenhauer</surname><given-names>ES</given-names></name><name><surname>Moran</surname><given-names>C</given-names></name><name><surname>Lazenby</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>KC</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><name><surname>Boots</surname><given-names>LR</given-names></name></person-group><article-title>Androgen Excess in Women: Experience with Over 1000 Consecutive Patients</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><issue>2</issue><fpage>453</fpage><lpage>462</lpage><?supplied-pmid 14764747?><pub-id pub-id-type="pmid">14764747</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. J Clin Endocrinol Metab. 2004;89(2):453&#x02013;62.<pub-id pub-id-type="pmid">14764747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Amiri</surname><given-names>M</given-names></name><name><surname>Ramezani Tehrani</surname><given-names>F</given-names></name><name><surname>Nahidi</surname><given-names>F</given-names></name><name><surname>Bidhendi Yarandi</surname><given-names>R</given-names></name><name><surname>Behboudi-Gandevani</surname><given-names>S</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis</article-title><source>Clin Endocrinol</source><year>2017</year><volume>87</volume><issue>3</issue><fpage>217</fpage><lpage>230</lpage></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Amiri M, Ramezani Tehrani F, Nahidi F, Bidhendi Yarandi R, Behboudi-Gandevani S, Azizi F. Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. Clin Endocrinol. 2017;87(3):217&#x02013;30.</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>BO</given-names></name><name><surname>Bolour</surname><given-names>S</given-names></name><name><surname>Woods</surname><given-names>K</given-names></name><name><surname>Moore</surname><given-names>A</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name></person-group><article-title>Visually scoring hirsutism</article-title><source>Hum Reprod Update</source><year>2009</year><volume>16</volume><issue>1</issue><fpage>51</fpage><lpage>64</lpage></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Hum Reprod Update. 2009;16(1):51&#x02013;64.</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferriman</surname><given-names>D</given-names></name><name><surname>Gallwey</surname><given-names>JD</given-names></name></person-group><article-title>Clinical assessment of body hair growth in women</article-title><source>J Clin Endocrinol Metab</source><year>1961</year><volume>21</volume><issue>11</issue><fpage>1440</fpage><lpage>1447</lpage><?supplied-pmid 13892577?><pub-id pub-id-type="pmid">13892577</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21(11):1440&#x02013;7.<pub-id pub-id-type="pmid">13892577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferriman</surname><given-names>D</given-names></name><name><surname>Purdie</surname><given-names>AW</given-names></name></person-group><article-title>The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients</article-title><source>Postgrad Med J</source><year>1983</year><volume>59</volume><issue>687</issue><fpage>17</fpage><lpage>20</lpage><?supplied-pmid 6866869?><pub-id pub-id-type="pmid">6866869</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Ferriman D, Purdie AW. The aetiology of oligomenorrhoea and/or hirsuties: a study of 467 patients. Postgrad Med J. 1983;59(687):17&#x02013;20.<pub-id pub-id-type="pmid">6866869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Bizuneh</surname><given-names>AD</given-names></name><name><surname>Joham</surname><given-names>AE</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Mousa</surname><given-names>A</given-names></name><name><surname>Earnest</surname><given-names>A</given-names></name><name><surname>Hawley</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Azziz</surname><given-names>R</given-names></name><name><surname>Arlt</surname><given-names>W</given-names></name><name><surname>Tay</surname><given-names>CT</given-names></name></person-group><article-title>Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines</article-title><source>Hum Reprod Update</source><year>2025</year><volume>31</volume><issue>1</issue><fpage>48</fpage><lpage>63</lpage><?supplied-pmid 39305127?><pub-id pub-id-type="pmid">39305127</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Bizuneh AD, Joham AE, Teede H, Mousa A, Earnest A, Hawley JM, Smith L, Azziz R, Arlt W, Tay CT. Evaluating the diagnostic accuracy of androgen measurement in polycystic ovary syndrome: a systematic review and diagnostic meta-analysis to inform evidence-based guidelines. Hum Reprod Update. 2025;31(1):48&#x02013;63.<pub-id pub-id-type="pmid">39305127</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Janse</surname><given-names>F</given-names></name><name><surname>Eijkemans</surname><given-names>MJC</given-names></name><name><surname>Goverde</surname><given-names>AJ</given-names></name><name><surname>Lentjes</surname><given-names>EGWM</given-names></name><name><surname>Hoek</surname><given-names>A</given-names></name><name><surname>Lambalk</surname><given-names>CB</given-names></name><name><surname>Hickey</surname><given-names>TE</given-names></name><name><surname>Fauser</surname><given-names>BCJM</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name></person-group><article-title>Assessment of androgen concentration in women: liquid chromatography&#x02013;tandem mass spectrometry and extraction RIA show comparable results</article-title><source>Eur J Endocrinol</source><year>2011</year><volume>165</volume><issue>6</issue><fpage>925</fpage><lpage>933</lpage><?supplied-pmid 21969522?><pub-id pub-id-type="pmid">21969522</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Janse F, Eijkemans MJC, Goverde AJ, Lentjes EGWM, Hoek A, Lambalk CB, Hickey TE, Fauser BCJM, Norman RJ. Assessment of androgen concentration in women: liquid chromatography&#x02013;tandem mass spectrometry and extraction RIA show comparable results. Eur J Endocrinol. 2011;165(6):925&#x02013;33.<pub-id pub-id-type="pmid">21969522</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>W</given-names></name><name><surname>Vesper</surname><given-names>H</given-names></name></person-group><article-title>Toward Excellence in Testosterone Testing: A Consensus Statement</article-title><source>J Clin Endocrinol Metab</source><year>2010</year><volume>95</volume><issue>10</issue><fpage>4542</fpage><lpage>4548</lpage><?supplied-pmid 20926540?><pub-id pub-id-type="pmid">20926540</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Rosner W, Vesper H. Toward Excellence in Testosterone Testing: A Consensus Statement. J Clin Endocrinol Metab. 2010;95(10):4542&#x02013;8.<pub-id pub-id-type="pmid">20926540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Dewailly</surname><given-names>D</given-names></name><name><surname>Lujan</surname><given-names>ME</given-names></name><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Cedars</surname><given-names>MI</given-names></name><name><surname>Laven</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name></person-group><article-title>Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society</article-title><source>Hum Reprod Update</source><year>2014</year><volume>20</volume><issue>3</issue><fpage>334</fpage><lpage>352</lpage><?supplied-pmid 24345633?><pub-id pub-id-type="pmid">24345633</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2014;20(3):334&#x02013;52.<pub-id pub-id-type="pmid">24345633</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>